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General introduction
1.1 INTRODUCTION ^ , ,,, , ,4y^, ,j,,;' ;..,,•.,,; - , ,^y4.w,,^
Pulmonary hypertension develops in response to a large variety of diseases (1). Re-
gardless of its etiology, chronic pulmonary hypertension leads to structural alterations
of the lung circulation, commonly called pulmonary vascular remodeling (2,3). In the
early phases of plexogenic arteriopathy, a characteristic form of pulmonary vascular
remodeling frequently associated with congenital heart defects, and hypoxia-induced
arteriopathy, these structural pulmonary vascular changes are quite similar, despite
clear differences between the inciting mechanisms. In later stages of the remodeling
process, increased pulmonary blood flow in patients with congenital heart disease or
chronic alveolar hypoxia in patients with chronic obstructive pulmonary disease
(COPD) may induce more disease specific structural patterns. A classic feature of the
remodeling process in chronic hypoxia-induced pulmonary hypertension is muscula-
rization of normally non-muscular arterioles and the presence of longitudinal smooth
muscle cells in the intima of small pulmonary arteries (4,5). Longstanding pulmonary
hypertension in patients with COPD will lead to right ventricular dilatation and hy-
pertrophy ('cor pulmonale') and may finally cause right ventricular failure (6,7). The
development of pulmonary hypertension is associated with an increased morbidity
and mortality in patients with COPD (7-9).
In patients with a left-to-right shunt due to congenital heart disease the remod-
eling process is characterized by plexogenic arteriopathy (10,11). In the early phase this
type of remodeling is, like in hypoxia-induced pulmonary hypertension, characterized
by medial hypertrophy and extension of smooth muscle cells into normally non-
muscular arterioles (12). In the more advanced stages intimal hyperplasia occurs,
whereas plexiform intimal lesions have developed in the irreversible stage (13). It is
believed diat structural pulmonary vascular changes constitute an important determi-
nant in the management and prognosis of children with congenital heart defects.
Several studies, however, indicate important discrepancies between pulmonary
vascular structure and hemodynamic data in individual patients with a congenital heart
defect (12,14-17). This discrepancy may point to a lack of understanding of flow/struc-
ture relationships. „, vi*.: ^-,-.».. -J , ,< -;.-. , ;
The pathogenesis of pulmonary vascular remodeling in patients with COPD
and congenital heart defects is poorly understood. Pulmonary vascular remodeling is an
active process that involves changes in several cellular processes like pulmonary vascular
smooth muscle cell growth and migration, pulmonary vascular smooth muscle cell
IJr
death, and production and degradation of extra-cellular matrix components (18). The
pulmonary vasculature is capable of sensing changes within its milieu, integrating these
signals via intercellular communications, and adapting through the local production of
mediators that influence structure as well as function (19,20). Especially the pulmonary
endothelial cell, lining the inner vessel wall, is suited to detect changes in hemodynamic
forces, such as shear stress and hydrostatic pressures, changes in PO2, vasoactive media-
tors and toxins. The variations in pulmonary vascular changes are probably explained
by the type and intensity of signals affecting endothelial cell function, the mediators
generated by the endothelial cells, their effect on the pulmonary vascular smooth
muscle cells and the underlying genetic predisposition of the patient. Genetically-
determined differences in (pulmonary) vascular reactivity have been shown in animals
and are likely to occur in man as well (21,22). Polymorphisms of genes of mediators
involved in vascular remodeling could be one of the explanations for these differences in
susceptibility for the development of pulmonary hypertension. For instance, in the
systemic circulation polymorphisms of genes of the renin angiotensin system (RAS)
(23-32) and endothelial nitric oxide synthase (eNOS) (33-37) have been associated
with an increased risk of cardiovascular diseases. With respect to the pulmonary circula-
tion, only very few data exist about an association between gene polymorphism and the
development of pulmonary hypertension.
^ This thesis aims at increasing insights into the mechanisms of pulmonary
o. vascular remodeling, in 1. children with congenital heart defects, 2. two rat models and
5 3. a model of chronic hypoxia-induced pulmonary hypertension in genetically modi-
12 fied mice. We investigated the role of angiotensin II (All) in this remodeling process,
the correlation between pulmonary vascular remodeling and pulmonary artery pressure
and the potential role of polymorphisms of genes of the RAS and eNOS in the develop-
ment of pulmonary hypertension induced right ventricular hypertrophy in patients
with severe COPD.
1.2 NORMAL PULMONARY CIRCULATION . -T, , - ....,
The circulation of the lung is complex and differs both functionally and structurally
from that in any other organ. The primary function of the pulmonary circulation is
the exchange of oxygen and carbon dioxide and not nutrients as in most other organs.
Optimal conditions for the exchange between blood and inspired air require a low
pulmonary artery pressure. The normal mean pulmonary artery pressure is around 15
mmHg (38). Moreover, the pulmonary circulation is unique in that it receives the
whole cardiac output, and in that it has the capacity to adapt to an increase in cardiac
output, without large alterations in pulmonary vascular pressure (39). Thus, the nor-
mal pulmonary circulation is characterized by a high flow, low pressure and low resis-
tance. Compared to the systemic circulation it has unique structural and functional
properties.
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1.2.1 Structural differences between the pulmonary and systemic circulation
The most important structural differences between the pulmonary and systemic cir-
culation are: 1. that for a given caliber, the medial thickness of pulmonary arteries is
considerably less than that of systemic arteries and 2. that their lumina are relatively
wider. These features reflect the high flow and low resistance in the pulmonary circu-
lation. Arterioles similar to those in the systemic circulation are not present in the pul-
monary circulation. In the acinus, a completely muscular pulmonary artery gives way
to a partially muscular artery and finally becomes a non-muscular artery. This small
non-muscular artery (<90-100u,m, > 10(lm), which is still larger than a capillary, is of-
ten referred to as arteriole or precapillary artery (40).
Also the capillary network of the lung differs from that of the systemic circula-
tion (41). In peripheral organs the arterioles break down into a brush-like bundle of
capillaries, which collect into a venule, whereas in the lung, capillaries form a dense
anastomosing hexagonal network without an obvious beginning or end.
Apart from pulmonary arteries that accompany the bronchi there are additional
branches known as supernumerary arteries, which do not follow the airways, but
sharply bend off the main artery and head straight for the alveolar parenchyma (42).
Bronchial arteries originate from the systemic circulation and provide nutrient
blood supply to the bronchi and major blood vessels. The media of bronchial arteries is
thicker than that of pulmonary arteries, although slightly diinner than that of systemic
arteries.
1.2.2 Functional differences between the pulmonary and systemic circulation
A major functional difference between the systemic and pulmonary circulation is die
response to a decrease in PO2. In the systemic circulation, a local decrease in PO2 in-
duces vasodilatation, allowing perfusion to increase and restore tissue PO2. In con-
trast, in the pulmonary circulation, a local decrease in PO2 induces vasoconstriction,
causing a decreased perfusion and thereby restoring the ventilation/perfusion ratio.
Although the observation of hypoxia-induced pulmonary vasoconstriction is
more than 50 years old, its biochemical mechanism remains largely unknown (43). It is
now becoming clear that the endothelium of the lung vessels plays an important role in
producing several different vasoactive substances like for instance All, nitric oxide
(NO) and endothelin I (ET-I) which not only play a role in modulating pulmonary
vascular tone, but also in pulmonary vascular remodeling.
1.3 PULMONARY HYPERTENSION
Pulmonary hypertension is a frequent and serious, often fatal disorder. Clinical symp-
toms include dyspnoea on exertion, fatigue and angina-like pain. Pulmonary hyper-
et,
Table 1. - Causes of plexogenic and hypoxic arteriopathy.
Plexogenic arteriopathy
Hypoxic arteriopathy
Congenital cardiovascular disease with a:
• left-to-right shunt
• transposition with intact ventricular septum
Hepatic disease, portal hypertension
Schistosomiasis
Anorexigens
HIV infection
Primary (unknown)
Chronic obstructive pulmonary disease
Upper airway obstruction
Alveolar hypoventilation
• on a central or
• neuromuscular basis
Thoracic skeletal disorders
High altitude
Hfaoenvoort and Moo/ (10,178)
5 tension is defined as mean pulmonary artery pressures in excess of 25 mmHg at rest or
g- in excess of 30 mmHg during exercise (44).
" Pulmonary hypertension can be the result of multiple and diverse etiologies
14 which include congenital heart defects, chronic lung disease, autoimmune disease,
HIV infection, hepatic disorders, thrombotic, pulmonary vasculitis, longstanding left
ventricular failure, mitral valve stenosis/insufficiency, drugs, etc. Moreover, it can be a
rapidly progressive and fatal illness of unexplained etiology (primary pulmonary hyper-
tension [PPH]) (45,46). All patients with longstanding pulmonary hypertension will
have structural pulmonary vascular changes. However, depending on the etiology
different structural patterns of pulmonary vascular lesions may develop. Plexogenic and
hypoxic arteriopathy are two common patterns of pulmonary vascular remodeling.
Their main causes are summarized in table 1.
If the primary etiology is known and the patient can be treated in time (correc-
tion of a congenital heart defect, etc) elevation of pulmonary artery pressure may
regress. Estimates of survival in PPH are often poor, although considerable variation in
these estimates does occur (47). Because it is out of the scope of this thesis to discuss all
causes of pulmonary hypertension in detail we will focus on pulmonary hypertension in
patients with congenital heart defects and in patients with COPD, two common causes
of pulmonary hypertension.
^ 1
V>.-'.'" Mi
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Chapter 1 15
PLEXOGENIC ARTERIOPATHY HYPOXIC ARTERIOPATHY
normal muscular
pulmonary artery
medial chickening
' • ' ' * > • : ' • * ' * ' <
§{"«•*•,••••'•' t i
concentric
laminar
*'••' intimal fibrosis
itl . " . . , . . . . . . ... , .
fibrinoid i j i v
: o
longitudinal
muscle bundles
plexiform
lesion
•Jr'ti:
normal
pulmonary arteriole
Figure i . '
> ^ - ^ v
X x
muscularization of arterioles
1.3.1 Pulmonary hypertension in congenital heart disease
Plexogenic arteriopathy is a characteristic type of pulmonary vascular remodeling
which may occur in congenital heart disease associated with an increased pulmonary
blood flow. Plexogenic arteriopathy is a sequence of structural pulmonary arterial
changes. In the final stage it includes the characteristic plexiform lesions (Figure 1)
(48). This type of structural pulmonary vascular changes may also be found in condi-
tions other than increased pulmonary blood flow due to congenital heart disease. The-
se conditions are summarized in table 1. The first structural changes in patients with
congenital heart disease associated with an increased pulmonary blood flow appear in
i t ; jltjf- i
the small muscular pulmonary arteries. These include an increase in medial thickness
and extension of smooth muscle cells into normally non-muscular arterioles. Another
feature of plexogenic arteriopadiy is intimal thickening, which may cause progressive
narrowing and even obliteration of the lumen. Intimal cell proliferation and concen-
tric-laminar intimal fibrosis are characteristic for this arteriopathy. In later stages of
plexogenic pulmonary arteriopathy, under sustained elevation of pulmonary arterial
transmural pressure, localized dilatation of pulmonary arteries may occur. The com-
bination of widening of the lumen and extreme thinning of the arterial wall produce
so called 'vein-like branches of arteries' (11). Clusters of vein-like branches are refer-
red to as 'angiomatoid lesions' and the combination of vein-like branches and angio-
matoid lesions are known as dilatation lesions. Advanced lesions in the sequence of
pulmonary vascular changes that form the pattern of plexogenic arteriopathy are fibri-
noid necrosis and plexiform lesions. A plexiform lesion consists of a dilated segment of
a pulmonary artery. In or adjacent to this dilated segment there is a destruction of the
arterial wall with thinning of the media. A plexus of narrow slit-like luminal spaces de-
velops within a dilated lumen. Advanced lesions, like concentric laminar intimal fi-
brosis, fibrinoid necrosis and plexiform lesions, are considered irreversible (13).
As long as increased pulmonary blood flow or elevated pulmonary artery pres-
sure persists, the process of pulmonary vascular remodeling may progress to irreversible
structural vascular changes. When fibrinoid necrosis or plexiform lesions are present,
plexogenic arteriopathy may even become progressive despite elimination of the cause
(13). Histological evaluation of structural pulmonary artery changes in an open lung
biopsy and hemodynamic evaluation by cardiac cadieterization are two techniques
commonly used to asses the state of the pulmonary vasculature and to determine oper-
ability. The grading system described by Heath and Edwards is most commonly used to
evaluate structural pulmonary changes in patients with a congenital heart defect (11).
However, in individual patients with congenital heart disease, preoperative hemody-
namic findings and postoperative clinical outcome do not always correlate with struc-
tural pulmonary artery changes (14,16,17).
In summary, the pathophysiology of plexogenic arteriopadiy in patients widi
congenital heart defects is poorly understood. Moreover, structural pulmonary vascular
changes in patients with congenital heart disease do not always correlate with hemody-
namic data.
1.3.2 Pulmonary hypertension in COPD . _, . . .,.
In 1946, Von Euler and Liljestrand were the first to report tJiat a decrease in alveolar
oxygen tension causes a rise in pulmonary arterial pressure (43). Since that time die ef-
fects of acute and chronic alveolar hypoxia on the pulmonary vasculature and the
mechanisms mediating this effect have been extensively studied. Up till now, how-
ever, it is not completely clear which substances and cells are involved in die regula-
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tion of hypoxia-induced vasoconstriction. Potential candidates will be discussed in
p a r a g r a p h 1 . 5 . - ••-- .•••.<-•• '' '"' — ' • ( ? ' • - • " : - >-= :mu;;^>=- • ^ b
Alveolar hypoxia occurs in a great variety of conditions which are summarized in
table 1. COPD is by far the major cause of respiratory insufficiency in the industrialized
countries and probably accounts for 90% of the cases of hypoxic pulmonary hyperten-
sion (49,50). As mentioned above alveolar hypoxia-induced vasoconstriction mini-
mizes the blood flow to hypoxic areas. Blood is directed to better ventilated areas of the
lungs, which restores the ventilation perfusion balance. However, if alveolar hypoxia
becomes chronic and more generalized, as in patients with COPD, the combination of
vasoconstriction and remodeling of pulmonary arteries may eventually cause severe
pulmonary hypertension, right ventricular hypertrophy and, finally, right ventricular
failure. Hypoxia-induced pulmonary arterial vasoconstriction and remodeling are
main factors responsible for this elevation of pulmonary artery pressure. Other factors
like mechanical compression of blood vessels by a high alveolar pressure, loss of alveolar
capillaries as occurs in emphysema, post-thrombotic lesions, an increased hematocrit
and dysfunctional endothelium may be additional causes (51-54).
If patients with COPD develop pulmonary hypertension and overload of the
right ventricle, they have developed a so called 'cor pulmonale', a descriptive term used
to denote enlargement of the right ventricle by either hypertrophy, dilatation, or both,
as a consequence of disorders and diseases of the respiratory system (55).
Alveolar hypoxia induces vasoconstriction but mainly in the small muscular and
pre-capillary arteries. As a consequence the most striking structural vascular changes
reside in the small pulmonary arteries, although functional as well as structural changes
have been described in pulmonary veins (56-58). The most characteristic pulmonary
vascular lesions in chronic hypoxic arteriopathy consist of an increased medial thick-
ness of small muscular pulmonary arteries and peripheral extension of smooth muscle
cells into normally non-muscular arterioles (muscularization of arterioles) (59).
Another feature is the presence of longitudinal smooth muscle cells in the intima and
sometimes in the media of arterioles. Small pulmonary veins may show similar changes
although to a lesser extent. Large muscular arteries may show mild medial thickening
(Figure 1).
Hypoxic pulmonary hypertension may be reversible when the oxygen content
of the alveolar air is restored to normal, as has been shown in high-altitude dwellers
during a stay at sea level (60). In rats, hypoxia-induced structural vascular changes
disappear upon restoring normoxia (61,62). Although pulmonary hypertension
progresses slowly in patients with COPD, its presence implies a poor prognosis. The
5-year survival rate is about 50% in most of the studies. In patients with COPD it is
evident that most of the vasodilator trials are of marginal benefit (63). Long-term
oxygen therapy (LTOT) may decrease pulmonary artery pressure (PAP) at rest and
during exercise and can reverse the progression of pulmonary hypertension, although
structural pulmonary changes and PAP rarely return to normal (64-66). LTOT can
reduce mortality in patients with COPD, although this improvement in survival is not
clearly associated with an improvement in pulmonary hemodynamics (67,68).
• • • : . - / < • - ' • • . - ^ • . . ( . • ! • : > : :
1 . 4 A N I M A L M O D E L S O F P U L M O N A R Y H Y P E R T E N S I O N .,-.., ;.,,. , . > , , , ,
Much of the progress in understanding the mechanisms of chronic pulmonary hyper-
tension comes from studies in animal models. Molecular and cellular biology techni-
ques have been successfully used to gain insights in pulmonary vascular biology (69).
Especially pharmacological and genetic interventions in these models may provide in-
formation on mediators and growth factors that play a crucial role in the regulation of
the remodeling process of pulmonary arteries. Several animal models of pulmonary
hypertension have been used like high pulmonary blood flow produced by syste-
mic-to-pulmonary shunts, venous obstruction, lung injury and chronic embolic ob-
struction of the vessel lumen (70,71). In this thesis we will focus on two classic models
of pulmonary hypertension, the chronic hypoxia and monocrotaline (MCT) models.
c /jypox;'o • '
High altitude-exposed (4300 m) calves and rats or rats exposed to chronic normobaric
hypoxia (10% O2) develop pulmonary hypertension and marked structural changes
in small pulmonary arteries and arterioles that are comparable with those developing
in humans under hypoxic conditions, and include right ventricular hypertrophy and
an increased hematocrit. Longitudinal smooth muscle cells in the intima of small arte-
ries, a classic feature of human hypoxic pulmonary vascular remodeling, however, has
not been observed in chronic hypoxic rats. For this reason some authors believe that
the rat is a poor animal model for the study of human pulmonary hypertension (72).
Afonocrota/me • • , , . . - , . ! , . .
Metabolic pyrolles of monocrotaline (MCT) are known to cause inflammation of
pulmonary vessels and endothelial damage (73-75). The net result is severe pulmona-
ry hypertension, which develops within 4 weeks after the administration of a single
dose of MCT (76). Structural pulmonary vascular changes resemble those described
under hypoxic conditions (77). The development of longitudinal smooth muscle cells
in the intima in this model has recently been described by Okada (78). However, the-
se authors could only show this after performing an additional unilateral pneumecto-
m y . •. . , - . • . . : . • • : . . . : , ; • . . , , ; • , ; . • ; : - S S
6enet;co//y o/tered m/ce > : • : . . , , , , » ! „ n ,. • ..
Genetically altered mice in which the expression of genes is either suppressed or en-
hanced have recently been used to elucidate the mechanisms of pulmonary vascular
remodeling. For instance, eNOS deficient mice show enhanced hypoxic pulmonary
vascular remodeling, pulmonary hypertension and right ventricular hypertrophy
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(79,80) , indicat ing that N O plays a crucial role in the counterbalance mechanism of
hypoxia-induced pu lmonary hypertension and pu lmonary artery remodeling. C h r o -
nic hypoxic mice partially deficient for hypoxia-inducible factor l a show impaired
physiological responses to chronic hypoxia (81).
Elevation of plasma atrial natriuretic pept ide (ANP) , a potent vasodilator,
attenuates the development of pu lmonary hypertension and right ventricular hyper-
t rophy in rats exposed to chronic hypoxia (82,83) . Transgenic mice that overexpress
A N P , also develop less pu lmonary hypertension when exposed to chronic hypoxia
compared to their nontransgenic lit termates (84), showing the decisive role of A N P in
the development of pu lmonary hypertension. ••-••— ••••« ••- ,
1.5 HUMORAL AND CELLULAR FACTORS INVOLVED IN PULMONARY VASCULAR
REMODELING
Chronic pulmonary hypertension is associated with changes in the production and re-
lease of potent vasoactive substances by the endothelium. Several vasoactive agents
possess growth-regulatory properties. As already suggested above, pulmonary vascular
remodeling may be the result of an imbalance of growth-inhibitory vasodilators and
growth-promoting vasoconstrictors. -• • •-••
: . ; - v • - r > * ••"• - . t o - - . - ' . . - • . - • ;: • •- : . : .••;. . '
1.5.1 Environmental influences • ' ' • — < " — ! -::. •,-.v • ! > • • • •-,•.••>-.
A variety of signals, acting on specific receptor sites of the pulmonary endothelial cell,
may alter the local production of mediators that influence pulmonary vascular struc-
ture as well as function (Figure 2). The endothelial cells seem to play a key role in
maintaining the dynamic structure/function relation.
Signals that activate endothelial cells range from hemodynamic forces, like shear
stress and hydrostatic pressures, to vasoactive mediators and toxins (85).
Recent data indicate that shear stress activates a genetic program that alters the
balance of mediators of remodeling by activating the transcription of genes of factors
such as nitric oxide synthase, transforming growth factor pi and platelet-derived
growth factor (19,86,87). Also chronic hypoxia can alter the expression of genes.
Hypoxia causes an increase in the mRNA contents of the genes encoding for vascular
endothelial growth factor (VEGF) and VEGF receptors in isolated perfused rat lung
preparations (88). Hypoxia-inducible factor-1 (HIF-1) is a potential mediator of
pulmonary vascular responses to hypoxia. HIF-1 is a transcription factor that is
expressed in response to hypoxia and that activates expression of genes involved in
erythropoiesis, angiogenesis, glycolysis, and modulation of vascular tone (81,89-92).
Among the hypoxia-inducible genes that contain functionally important HIF-1
binding sites are those encoding VEGF (93), inducible NOS (91) and endothelin 1
(94).
signals stretch shear stress inflammatory mediators
• : ' • . / • : • - w c f ^ . ' •• .1 • . ! • X , > ' . , ..;>:>)• ; ^ - • • . • , • M'I v ' ^ ' - . ! I . i i f ! - . ! / . . I V ' . ' j l . ' I
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vasoactive growth regulators
pulmonary
vascular
smooth muscle cell
F i g u r e 2 . - S i g n a l s , s e n s o r s a n d m e d i a t o r s o f v a s c u l a r r e m o d e l i n g . " K r « ( . - • . : • ! ' ' , . . , r )
Although many mediators are known to play a role in die regulation of pulmonary
vascular remodeling we will focus in this thesis on All (paragraph 1.5.4) and NO (pa-
ragraph 1.5.5) because they are important examples of mediators with vasoconstricti-
ve/growth promoting and vasodilatory/growth inhibitory properties respectively.
1.5.2 Genet ic i n f l u e n c e s . • ,, . .. ,, : ,
Several studies indicate a genetic component in the development of (primary) pulmo-
nary hypertension. A familial form of PPH has been described and characterized with
linkage to chromosome 2q31 -q32, suggesting a genetic predisposition in some instan-
ces of PPH (95). Moreover, women are affected twice as often as men (96). An increa-
sed incidence of PPH associated with appetite-suppressant drugs has been described
and raises the question whedier these patients have a genetic predisposition to develop
pulmonary hypertension (97). In genetically distinct strains of rats, differences in pul-
monary vascular reactivity are a consequence of a different susceptibility to hypoxia
(98,99). A heterogeneous susceptibility to chronic hypoxia has also been described in
human victims of chronic mountain sickness (22) and in cattle with Brisket disease
(100). Some patients widi COPD develop pulmonary hypertension and cor pulmo-
nale whereas others do not. Again, this heterogeneity in susceptibility may be due to
inherited differences in pulmonary vascular reactivity.
In the systemic circulation, recent studies have shown that polymorphisms of
the renin angiotensin system (RAS) and eNOS are associated with a number of cardio-
vascular diseases. Polymorphisms of genes encoding for components of the renin angio-
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tensin system include, for instance, the M ^ T polymorphism in the angiotensinogen
gene, the 287-base-pair insertion (I) / deletion (D) polymorphism at intron 16 of the
ACE gene and the A '"^C polymorphism in the angiotensin II type 1 receptor gene.
Polymorphisms of the eNOS gene include a 27-bp repeat polymorphism in intron 4 of
the eNOS gene (eNOS a/b) and a G894T polymorphism in exon 7 of the eNOS gene.
The ACE DD genotype has been associated with left ventricular hypertrophy,
increased risk of myocardial infarction, cardiomyopathy and coronary artery disease
(23-27). Also polymorphisms in other genes of the renin angiotensin system, like the
M ^ ' T polymorphism in the angiotensinogen (AGT) gene and the A " ^ C polymor-
phism in the angiotensin II type 1 receptor (AGTjR) gene have been associated with
cardiovascular disease like essential hypertension, coronary heart disease and myocar-
dial infarction (28-32). With respect to the pulmonary circulation one study reports
that the ACE DD genotype is more prevalent in patients with PPH (101). However,
Morrell and co-workers have shown that people living at high altitude and who develop
hypoxia-induced pulmonary hypertension have a 6-fold higher frequency of the ACE
II genotype compared with those without (102).
Polymorphisms of the eNOS gene could be another explanation for differences
in susceptibility to develop pulmonary hypertension. As discussed in paragraph 1.5.5
alterations of eNOS gene expression in the lung may play a role in the pathogenesis of
pulmonary hypertension. Individuals with the eNOS aa genotype have significantly
higher levels of circulating plasma NO metabolites compared to individuals with the
eNOS ab and bb genotype (103) and may therefore be less susceptible to develop
pulmonary hypertension. Like polymorphisms of the RAS genes, polymorphisms of
the eNOS gene have been associated with cardiovascular diseases. The eNOS aa geno-
type has been associated with the development of coronary artery disease (33). The TT
genotype of the eNOS gene G894T variant has been reported to be a strong risk factor
for essential hypertension, myocardial infarction and coronary spasm (34-37). There
are, however, no reports indicating an association between a/b and G894T polymor-
phisms of the eNOS gene and the development of pulmonary hypertension and/or
right ventricular hypertrophy in patients with PPH or secondary pulmonary hyperten-
sion.
1.5.3 Changes in pulmonary artery composition during the development of
pulmonary hypertension
The earliest structural changes in experimental models of pulmonary hypertension are
found in the adventitia of pulmonary arteries. Adventitial fibroblasts proliferate, hy-
pertrophy, increase the production of matrix proteins and convert into a contracti-
le-like cell in response to hypoxia or mechanical stress (104-107). These structural
changes of the adventitia may have functional effects on the ability of the pulmonary
vasculature to respond to vasoconstrictor and vasodilator stimuli. Several studies have
shown that vascular wall cells in adult organisms express genes or gene products cha-
racteristic of earlier developmental states. In response to injury these include tropoel-
astin, fibronectin, tenascin, etc. (108-110). Moreover, genes such as those for smooth
muscle-specific O-actin, desmin or myosin are down-regulated when adult cells proli-
ferate and migrate following injury (111,112). Thus, a series of changes in smooth
muscle cell phenotype occurs during the vascular remodeling process and also during
pulmonary vascular remodeling. In the distal pulmonary vasculature, precursor cells
differentiate into mature smooth muscle cells and migrate, so that normally
non-muscular arterioles become abnormally muscular (113). In the more proximal
vasculature, medial thickening of larger pulmonary arteries is caused by smooth mus-
cle cell hypertrophy, hyperplasia and deposition of extracellular matrix components.
A subset of vascular smooth muscle cells increase their replicating and matrix protein
synthesizing properties (114-117). For instance, hypoxia selectively induces prolifera-
tion in a subset of (meta-vinculin-negative) cells in the bovine neonatal pulmonary ar-
terial media (118). Smooth muscle cells of the media may differentiate into a more
synthetic phenotype, producing extracellular matrix components, like elastin, colla-
gen and glycoproteins (119-121). Finally, intimal proliferation occurs as a result of
migration of smooth muscle cells from the media into the subintima, where they pro-
duce extracellular matrix components. In advanced plexogenic arteriopathy, prolife-
ration of endothelial cells and collagen synthesis has been demonstrated within plexi-
. T* form lesions (121,122). Some studies have shown that activation of vascular elastase
; a. plays a role in the development of structural pulmonary artery changes (123). Frag-
g mentation of the internal elastic lamina is one of the first structural events observed in
22 pulmonary hypertension, which implies the activation of elastases in the pulmonary
artery (124). Inhibition of elastase activity with serine elastase inhibitors has been
shown to prevent or attenuate structural pulmonary vascular changes in both hypo-
xia- and MCT-induced pulmonary hypertension (125,126).
Thus, in response to injury, pulmonary vascular wall cells express genes or gene
products characteristic of earlier developmental states. A subset of vascular wall cells
increases their replicating and matrix protein synthesizing properties and thus
contribute to pulmonary vascular remodeling that characterizes chronic pulmonary
hypertension. mu
1 . 5 . 4 T h e r o l e o f a n g i o t e n s i n I I ( A l l ) i n p u l m o n a r y h y p e r t e n s i o n •*.•.,• -•"
An important function of the pulmonary vascular endothelium is the cleavage of cir-
culating, inactive angiotensin I (AI) to the potent vasoconstrictor All, by the action of
angiotensin I converting enzyme (ACE). It is known that the renin angiotensin sy-
stem (RAS) is activated in PPH and secondary pulmonary hypertension (127,128).
The most important effects of All in the pulmonary circulation are summarized in ta-
ble 2. Apart from its vasoconstrictive action, All is known to induce structural arterial
changes, like matrix protein synthesis and smooth muscle cell hypertrophy and proli-
feration (129-132). Right ventricular ACE expression is upregulated during die deve-
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Table 2. - Angiotensin I I mediated effects in animal models of pulmonary hypertension.
Right ventricular hypertrophy T (133,141,179M84) <-» (185*,186,187,188*,189)
Pulmonary artery pressure T (141,179*,180,182,183,186) <-> (185*,187, 188*,189)
Pulmonary artery
T (141,180,181,183,186,187,189) <-> (188*, 189*)medial thickness
Smooth muscle cell
apoptosis
proliferation
Matrix components
synthesis
degradation
1 ( ,180,1
7
T (141,179*)
T (179*,186)
7
Studies in chronic hypoxia- and MCT *- induced pulmonary hypertension
lopment of hypoxia-induced right ventricular hypertrophy and may play a role in the
pathogenesis of right ventricular hypertrophy secondary to hypoxic pulmonary hy-
pertension (133). In animal models, most workers report a decrease in whole lung
ACE activity during the development of pulmonary hypertension (77,134-137).
Morrell and co-workers, however, showed that ACE expression is increased in the
wall of small pulmonary arteries during the development of hypoxic pulmonary hy-
pertension (138). In addition, marked longitudinal variation in ACE expression along
die normal vasculature was demonstrated. The highest ACE levels were found in
small pulmonary arteries. Also in patients with PPH it has been shown that ACE im-
munoreactivity is markedly increased in the endothelium and subendothelial neointi-
mal regions of pulmonary arteries compared to normal pulmonary arteries (139).
Thus, local overproduction of All by ACE could play an important role in pulmonary
artery remodeling (140), probably via stimulation of proliferative activity of pulmo-
nary smootii muscle cells (141). Both ACE inhibitors and ATI receptor blockers are
known to attenuate the development of pulmonary hypertension, medial thickening
of pulmonary arteries and right ventricular hypertrophy, especially in rats exposed to
chronic hypoxia. In MCT induced pulmonary hypertension most studies show no ef-
fect of ACE inhibition or ATI receptor blockade on pulmonary vascular remodeling,
right ventricular hypertrophy and PAP (see table 2).
In conclusion, there is increasing evidence that AH plays a crucial role in the
development of hypoxia-induced pulmonary hypertension. Early intervention with
ACE inhibitors could, in theory, prevent the development of pulmonary vascular
remodeling and the advent of associated right heart failure. However, no improvement
in functional capacity or survival has been demonstrated with ACE inhibitors in
patients with COPD (63,142-147), again showing the divergence between pulmonary
vascular structure and function. ' >>•.--!. •, . • •
Table 3. - NO mediated effects in animal models of pulmonary hypertension.
Right ventricular hypertrophy 4-(79,164-166,190"-193) <-» (164)
Pulmonary artery pressure 4- (79,15Z,153,160,166,190",193) <-> (165)
Pulmonary artery medial thickness 4. (79,160,164-166,190» -192) <-» (164)
Smooth muscle cell
apoptosis ?
proliferation ?
Matrix components |
synthesis ? j
degradation ? 'i
• Studies in both chronic hypoxia and MCT induced pulmonary hypertension
1.5.5 The role of NO in pulmonary hypertension
Nitr ic oxide is a po ten t vasodilator, which is synthesized from L-arginine by nitr ic oxi-
de synthase ( N O S ) (148) . T h e r e are three isoforms of N O S : neuronal const i tut ive n i -
tric oxide synthase ( n N O S ) , endothelial nitric oxide synthase ( e N O S ) and inducible
nitric oxide synthase ( iNOS) (148) . T h e role of N O in the systemic circulation is well
jg described. Its role in the pu lmonary circulation, particularly in modu la t ing the res-
g- ponse to hypoxia is, however, less well documen ted . T h e mos t impor t an t effects of
«5 NO in die control of pulmonary vascular structure and function are summarized in
24 table 3.
Under normal conditions, most studies report that basal NO production by
pulmonary endothelial cells contributes to the maintenance of basal pulmonary
vascular tone and is involved in the decline of the pulmonary vascular resistance during
exercise (149,150). Inhibition of the synthesis of NO markedly enhances the pulmo-
nary pressor response to acute hypoxic challenges (151,152). From these experiments it
was concluded that an increased NO activity during acute hypoxia probably represents
a physiological defence mechanism, limiting an excessive vasoconstrictive response of
die pulmonary vasculature.
Studies in experimental animals and in humans have yielded contradictory
results with respect to eNOS expression under chronic hypoxic conditions. Endothe-
lium-dependent pulmonary artery relaxation is impaired in rats exposed to chronic
hypoxia and in patients with COPD (54,153,154), suggesting reduced expression of
eNOS. In patients with PPH and secondary pulmonary hypertension, however, both
an increased and decreased expression of eNOS has been reported (155-157). In lungs
of chronic hypoxic rats several studies have shown an increased expression of nNOS,
eNOS and iNOS mRNA's (158-160). One study shows that in chronic hypoxia a rise
in PAP is associated with continuing release of NO (161). However, hypoxia decreases
the expression of eNOS mRNA in human pulmonary endothelial cells in culture
(162,163).
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Mice with a congenital deficiency in the eNOS gene show an enhanced pulmo-
nary vascular remodeling, right ventricular hypertrophy and pulmonary hypertension
as compared to wild-type animals indicating a pivotal (counterbalancing) role for NO
in the development of hypoxia-induced pulmonary hypertension (79).
Chronic inhalation of NO attenuates pulmonary vascular remodeling in
chronic hypoxic rats (164-166). The mechanism by which inhaled NO attenuates
hypoxic remodeling is believed to be secondary to the decrease in PAP. NO itself is a
vasodilator, but has also been shown to induce vasodilatation by inhibiting endothelial
production of the potent vasoconstrictors ET-I and PDGF-B (167). An alternative
explanation is that inhaled NO alters cellular mechanisms involved in pulmonary
vascular remodeling. NO donors have been demonstrated to be antimitogenic in aortic
vascular smooth muscle cell cultures (168-170). Attenuation of the muscularization of
the pulmonary arterioles could be a result of a direct inhibitory effect on pulmonary
artery smooth muscle cell growth. In humans, inhalation of NO has been shown to be
beneficial in some but not all conditions complicated by elevated pulmonary vascular
resistance (171-174). For instance, in COPD, where hypoxic vasoconstriction is
important in maintaining the ventilation/perfusion matching, NO inhalation may
worsen pulmonary gas exchange (175-177).
1.6 HYPOTHESIS " ' - ' •>-- ; j[
Our main hypothesis is that mediators that control the growth of pulmonary vascular as
smooth muscle cells are also involved in the development of pulmonary vascular re-
modeling in pulmonary hypertension.
From this main hypothesis we deduced the following sub-hypotheses:
1. Angiotensin II is an important mediator of vascular remodeling in pulmonary
hypertension.
2. Vascular remodeling in pulmonary hypertension correlates with pulmonary
artery pressure.
3. Polymorphisms of genes that contribute to vascular remodeling are risk factors
for the development of pulmonary hypertension.
The role of All in pulmonary vascular remodeling was studied in chapters 3 and
4. The correlation of pulmonary vascular structure and pulmonary artery pressure was
investigated in chapter 2 (children with congenital heart disease), chapter 3 (chronic
hypoxic and MCT treated rats) and chapter 4 (tissue ACE-deficient mice). The role of
gene polymorphisms in the development of pulmonary hypertension in patients with
COPD was investigated in chapter 5 (ACE I/D, AGT, R A» "*C and AGT M ^ T )
and chapter 6 (eNOS G894T and a/b). In chapter 7 the data obtained in the studies
will be discussed.
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CHAPTER 2
Evaluation of pulmonary vascular hemodynamics
and structure and their relation with clinical
outcome in children with congenital heart disease
>'; ; : • • ' ; . « H ;
S U M M A R Y > ' & ! ' • • • • > • ' " • • ' • • .
To determine the correlation between hemodynamics, structural pulmonary ar-
terial changes and clinical outcome, we retrospectively studied hemodynamic
and histological data and outcome in a group of 47 children with complex con-
genital heart disease.
Pulmonary artery pressures correlated weakly with increased muscularity of the
pulmonary arterial tree (r - 0.46 to 0.67; p < 0.05) and with advanced
plexogenic arteriopathy (p < 0.01). Diastolic pulmonary artery pressures lower
than 25mmHg or pulmonary vascular resistances lower than 6 WU.rn^ were
never found in patients with features of advanced plexogenic arteriopathy.
Perioperative mortality, associated with acute pulmonary hypertensive crises,
*• correlated with increased arterial muscularity (p = 0.01), but not with ad-
§_ vanced plexogenic arteriopathy. Pulmonary hypertensive crises did not corre-
5 late with preoperative hemodynamic parameters. Of 15 survivors, 5 showed
~ persistent pulmonary hypertension at follow up (69 ± 39 months; mean ± SD).
However, no correlation existed between preoperative hemodynamic parame-
ters or the histologic presence of advanced plexogenic arteriopathy and persis-
tent pulmonary hypertension after surgery. All 3 patients with plexiform le-
sions showed persistent pulmonary hypertension (p - 0.02).
Conclusions: We found only limited correlations between hemodynamic data
and pulmonary plexogenic arteriopathy. Perioperative mortality due to acute
pulmonary hypertensive crises was associated with increased muscularity of
the pulmonary arterial tree, but could not be predicted from preoperative
hemodynamics or the presence of advanced plexogenic arteriopathy. Both
hemodynamic and histologic assessment of plexogenic arteriopathy were of
limited predictive value for persistent pulmonary hypertension after corrective
surgery. Only plexiform lesions were predictive for persisting pulmonary hyper-
tension.
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Pulmonary plexogenic arteriopathy is thought to constitute a serious threat to chil-
dren with congenital heart disease and increased pulmonary blood flow or increased
pulmonary artery pressures. It is believed that as long as increased pulmonary blood-
flow or elevated pressure in the pulmonary arteries persists, the process of plexogenic
arteriopathy may progress towards a "point of no return", at which the process beco-
mes irreversible and precludes a curative effect of surgical repair of the cardiac disease
(1,2). In Fontan or Norwood-like procedures, even a slight postoperative increase in
the resistance of the pulmonary vascular bed will cause pulmonary hypoperfusion,
which may easily result in clinical deterioration. The techniques most commonly used
to assess the state of the pulmonary vasculature and to determine operability in chil-
dren with congenital heart disease are hemodynamic evaluation by cardiac catheteri-
zation (3,4) and histological evaluation of structural pulmonary vascular changes in
an open lung biopsy (1,5-7). However, important discrepancies between hemodyna-
mic data and structural pulmonary vascular changes have been reported in individual
patients with plexogenic arteriopathy (6,8-11), hampering the interpretation of such
findings. Furthermore, although widely used for over thirty years, data on the predic-
tive value of both techniques with regards to outcome are scarce (1,11-13). The pur-
pose of the present study is to correlate structural pulmonary vascular changes and he-
modynamic data, and relate the findings to clinical outcome in infants and children
with complex congenital heart disease.
METHODS
. 47 patients (29 male, 18 female) with congenital heart disease were included
in this retrospective study. Hemodynamic and histological data were obtained be-
tween 1983 and 1994.
£««£ ft'tfHf jpw/mmi Biopsy specimens were taken as an isolated procedure or
during cardiac surgery in children (biopsy group). In addition, specimens taken at
autopsy were included in the study (autopsy group). Lung tissue was fixed in 10%
phosphate-buffered formalin (pH 7.4), and paraffin embedded. Five |!m sections were
cut at various levels and stained with hematoxylin-eosin, Elastic Van Gieson stain and
Perls' iron stain. All specimens were re-examined independently by two pathologists
(CAW, RJS), who were unaware of the diagnosis and hemodynamic data. Only the age
of the patient was revealed. Pulmonary vascular lesions were described according to
Wagenvoort and Mooi (2). Morphologic features such as medial hypertrophy, muscu-
larization of arterioles, cellular intimal proliferation and concentric-laminar intimal
fibrosis were scored semi-quantitatively with regard to severity and frequency (0 =
absent, 1 = mild, 2 = moderate, 3 = severe), as described earlier (2). In evaluating the
muscularity of the pulmonary arterial tree, the scores for medial hypertrophy and
muscularization of arterioles were adjusted to the age of the patient (14-16). Subse-
quently, a consensus session revealed the definite scores. For the overall degree of
muscularity a single composite score, the total muscularity score (TMS, 0 = normal, 1 =
mildly increased, 2 = moderately increased, 3 = severely increased), was obtained on the
basis of the scores for medial hypertrophy and arteriolar muscularization. Dilatation
lesions, fibrinoid necrosis and plexiform lesions were documented as present or absent.
The presence of plexiform lesions, fibrinoid necrosis, dilatation lesions or concentric-
laminar intimal fibrosis was considered as "advanced pulmonary plexogenic arterio-
pathy". ,
//wz0t/K«d/»z'r <&/a. Cardiac catheterization was performed in all patients under
general anesthesia. Data on pulmonary and systemic arterial and venous pressures,
pulmonary blood flow, shunt size and pulmonary and systemic vascular resistance were
collected. Pulmonary vascular resistance was determined using pulmonary blood flow,
calculated with the Fick principle using assumed oxygen consumption. Pulse pressure
and the ratios of pulmonary-to-systemic pressure and pulmonary-to-systemic vascular
resistance were calculated. :• ; ' „•-.,., • i
/b//otf «/> d<7ta. Outcome was assigned to short-term and mid-term outcome.
Perioperative death associated with pulmonary hypertensive crises was studied as
short-term outcome variable, where ^rw/ifwft'w */<?*«/> M><« *&/?««/<« *&<«/» */«mzg or
jw'fA/'w 27 d<yjd/£fr cWwc tt<r£f7j. Acute pulmonary hypertensive crises were defined as
events of progressive and profound pulmonary hypertension and/or systemic desatura-
tion, in the absence of obstruction of the pulmonary artery, combined with a decreased
systemic circulation. In patients who underwent a univentricular repair, perioperative
death associated with pulmonary hypoperfusion was studied as outcome variable.
f. Persistent pulmonary hypertension was defined as a loud second heart
sound at physical examination, electrocardiographic evidence of right ventricular
hypertrophy and echocardiographic features suggestive for elevated pulmonary artery
pressure, in the absence of residual cardiac lesions.
StafMft'frf/rfwtf/y.fw. Patients in the autopsy and biopsy groups were analysed sepa-
rately because the indications to obtain lung tissue were dissimilar in both groups.
Hemodynamic data were correlated with histologic findings using Pearson's correla-
tion coefficient. Categorical data were compared by Fisher's exact test. Statistical
comparisons of hemodynamic and histologic data between groups of patients were
made using the Student's f test or Mann-Whitney U test when distribution was not
normal. In the biopsy group comparisons of data were made between patients with and
without clinical features of pulmonary hypertension during follow up, using the same
tests. A value of p < 0.05 was considered significant.
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Table 1 . - Anatomical Diagnosis.
VSD
<
cAVSD <
TGA <
Truncus arteriosus
ASO wi th/wi thout PAPVC
TAPVC
Tricuspid atresia
Fallot
Others
»isolated
» with leftsided obstructive lesions
»isolated
• complex
» complex
• complex
6
5
6
3
9
1
5
1
3
6
2
47
ASD indicates atrial septal defect; cAVSD, complete atrioventricular septal defect; PAPVC, partial
abnormal pulmonary venous connection; TAPVC, total abnormal pulmonary venous connection;
TGA, transposition of the great arteries; VSD, ventricular septal defect; complex indicates with
associated lesions; n, number of patients.
RESULTS • ''• • : • ;•'• -
Genera/
In the study period, 47 patients underwent histologic and hemodynamic evaluation
of the pulmonary vasculature. The total study group consisted of 29 males and 18 fe-
males, with a variety of complex congenital heart diseases (table 1). The median age at
the time of the lung biopsy was 6.5 months with a range from 1 day to 16.8 years. The
age distribution and the distribution of histological features in relation to age are
shown in Figure 1. One patient had two lung biopsies with cardiac catheterizations.
Three biopsies were taken as an isolated procedure and 14 during cardiac surgery (bi-
opsy group, n = 17). Thirty-one specimens were taken at autopsy (autopsy group, n =
31). For the whole group the median time period between collection of lung specimen
and hemodynamic data was 1,0 month, ranging from 3 days - 24 months. In 4 pa-
tients this period exceeded 6 months. Baseline characteristics of the autopsy and biop-
sy groups are shown in table 2. Pulmonary hemodynamics of the total study populati-
on are summarized in table 3.
y4«ro/>jry r^o«/). In the autopsy group, 26 of 31 patients had undergone cardiac
surgery. In 9 out of the 21 patients who had undergone a biventricular repair,
perioperative death was associated with pulmonary hypertensive crises. Preoperative
hemodynamic parameters of these 9 patients did not differ significantly with those
from patients who died perioperatively without pulmonary hypertensive crises (n = 4)
or patients who died after the perioperative period (n = 8). Of the 5 patients who had a
number of patients
i
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2.
MH
MA
ICP
CUF
DL
FN
PL
8
0
0
0
0
0
15
15
2
0
2
1
2
2
0
0
0
0
0
4
0
0
0
0
0
1
1
0
*
1
1
1
3
4
2
1 j
1 "
0
1
20 - I
1 5 -
1 0 -
5 -
0 - "
MH
MA
ICP
CUF
DL
FN
PL
• Medial Hypertrophy
• Muscularisation of Arterioles
• Intimal Cellular Proliferation
• Concentric Laminar Intimal Fibrosis
• Dilatation Lesions
• Fibronoid Necrosis " *-'- • • -
• Plexiform Lesions
•>,?,;
.- .v
0-3 3-12 1-2 2-4
months months year year
Figure 1. - Age distribution and the distribution of histologicaL
features in relation to age. / / : Autopsy patients; • : Biopsy patients.
univentricular repair, 3 died perioperatively due to pulmonary hypoperfusion, whereas
2 died after the perioperative period. Preoperative hemodynamic data did not differ
between the former and the latter.
Zfz'o/vy^ wtt^ ). In the biopsy group, 2 of the 17 patients died of causes not related
to pulmonary vascular disease (1 infectious disease, 1 during a later surgical procedure)
after 55 and 11 months respectively. The remaining 15 patients are still alive with a
mean follow up of 69 ± 39 months (mean ± SD), ranging from 14 months to 12.3 years.
Five of these patients showed clinical features of persistent pulmonary hypertension in
the absence of residual cardiac lesions.
//wjfl^ /ywrfm/'r-Awrtf/ogj'f com-Aifto/z. In the autopsy group, systolic, diastolic and
mean pulmonary artery pressure, pulmonary pulse pressure and the pulmonary-to-
systemic pressure ratio correlated significantly with the severity of medial hypertrophy
(r = 0.55, r = 0.46, r = 0.51, r = 0.60 and r = 0.60 respectively; all p < 0.05), arteriolar
muscularization (r = 0.53, r = 0.46, r = 0.50, r = 0.57 and r = 0.56 respectively; all p <
0.05) and total muscularization score (r = 0.59, r = 0.46, r = 0.54, r = 0.67 and r = 0.64
respectively; all p < 0.05). Pulmonary vascular resistance was correlated significantly
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Table 2. - Patient characteristics of the autopsy and biopsy groups,
group autopsy biopsy
n*
median age (mo)
(range)
M:F
hemodynamics
syst PAP
diast PAP
mean PAP
pulse pressure
PAP/SAP ratio
PVR
PVR/SVR ratio
histology
MH
MA
TMS
APA
31
4.5
(0.1-192)
2.8: 1
(mean ± SD)
43 ±22
21 ±11
30 ±15
22 ±14
0.56 ±0.34
4.6 ±4.5
0.49 ± 0.99
1.3 ±1.1
1.2 ±1.1
1.3 ±1.2
0/31
17
8.5
(3.1-201)
0.9 : 1
(mean ± SD)
60 ±20
26 ±10
41 ±15
34 ±12
0.64 ±0.27
8.0 ±3.5
0.32 ± 0.14
1.5 ±1.1
1.3 ±1.0
1.6 ±1.1
5/17
P
P
P
P
P
ns
ns
- 0.016
ns
-0.02
- 0.006
ns
-0 .01
ns
ns
ns
ns
- 0.003
APA indicates features of advanced plexogenic arteriopathy; MA, arteriolar muscularisation; M :
F, sex ratio; MH, medial hypertrophy; n, number of specimens; PAP, pulmonary artery pressure
(mmHg); syst, systolic; diast, diastolic; PVR, pulmonary vascular resistance (WU.m*); SAP, sys-
temic arterial pressure; TMS, total muscularity score; * one patient had two lung tissue specimen^
with concomitant hemodynamic data, see text.
with medial hypertrophy only (r = 0.39, p < 0.05). Pulmonary blood flow, shunt size,
pulmonary-to-systemic resistance ratio and pulmonary venous pressures showed no
correlation with the features of arterial muscularity.
In the biopsy group, none of the hemodynamic parameters significantly corre-
lated with the features of arterial muscularization or the presence of cellular intimal
proliferation. Pulmonary artery pressures and pulmonary-to-systemic pressure ratio
were significantly higher in patients with histologic lesions of "advanced plexogenic
arteriopathy" compared to those without these features. This holds for the systolic
pulmonary artery pressure (75 ± 18 vs. 53 ± 18 mmHg, p = 0.03), the diastolic pulmo-
nary artery pressure (36 ± 11 vs. 21 ± 5 mmHg, p = 0.002), the mean pulmonary artery
pressure (53±l4vs36±12 mmHg, p = 0.02), and the pulmonary-to-systemic pressure
ratio (0.94 ± 0.19 vs. 0.51 ± 0.18, p = 0.01).
None out of 7 patients with pulmonary vascular resistance lower than 6WU.m^
and none out of 9 patients with diastolic pulmonary artery pressure lower than
25mmHg, cut-off values reported in earlier studies (8,11,17) showed features of
"Table 3. - Pulmonary hemodynamic characteristics of the total study population.
i
Qp (shuntsize)
mPAP (mmHg)
PVR (WU.m*)
mPVP (mmHg)
T
i
-
mean ±
T
-
mean ±
<4
4-7
>7
mean ±
T
-
mean ±
SD
SD
SD
SD
1
10
_
-
10
1.1 ±0.1
5
5
19 ±6
4
4
1
3.9 ± 2.6
-
10
8 ± 3
2
28
28
-
-
4.0 ± 4.3*
25
3
38 ± 14*
9
8
9
6.4 ±5.1
-
28
9 ± 2
3
4
_
4
-
0.6 ±
2
2
31 ±
-
2
1
8.1 ±
-
4
6±
0.2*
22
5.8
1
1.5
48
9.2
21
4
6
3
1
2
±0.8
5
1
±15*
2
-
4
±7.1
6
-
± 3 *
Total
48 #
31
5
12
2.8 ±3.6
37
11
35 ±16
15
14
15
6.3 ±5.1
6
42
9 ± 5
1
1, indicates normal pulmonary blood flow (Qp/Qs ratio: 0.8-1.2); 2, increased pulmonary blood
flow (Qp/Qs ratio > 1.2); 3, decreased pulmonary blood flow (Qp/Qs ratio < 0.8); 4, pulmonary ve-
nous congestion (pulmonary venous pressure > 17 mmHg). mPAP indicates mean pulmonary ar-
tery pressure (T> 20 mmHg); mPVP, mean pulmonary venous pressure (T > 17 mmHg); n, number
of patients; PVR, pulmonary vascular resistance; Qp, pulmonary blood flow; * significant differ-
ence with group I (p < 0.05). ft one patient had two lung tissue specimens with concomitant
hemodynamic data, see text.
advanced plexogenic arteriopathy in the lung biopsy, while 5 out of 10 patients with
pulmonary vascular resistance higher than 6WU.m^ and 5 out of 8 patients with a
diastolic pulmonary artery pressure higher than 25mmHg did show these features (p =
0.04 and p = 0.009 respectively, analysed for biopsy and autopsy groups together: p =
0.003 and p = 0.002 respectively; Figure 2).
S/rKffwrf-ywwctt'oH rorr^fto« w»>A j/wrf-rmw Ottrfow?. Patients who died
perioperatively associated with pulmonary hypertensive crises showed significantly
increased medial hypertrophy, arteriolar muscularization and a higher muscularization
score compared to those who died perioperatively without such crises (medial hyper-
trophy: 2.1 ± 0.9 vs. 0.5 ± 1.0 (p = 0.01); arteriolar muscularization: 1.8 ± 1.1 vs. 0.5 ±
1.0 (p = 0.04); muscularization score: 2.2 ±1.0vs. 0.5 ± 1.0 (p = 0.01, mean ±SD).
Sm<rtwrr-/««rft0H forrrtlaftow ux'/A ;»«/-*«•»* owfc-owiif. Preoperative hemody-
namic data from children with persistent pulmonary hypertension did not differ
significantly from those without persistent pulmonary hypertension. This holds for the
mean pulmonary artery pressure (50 ± 18 vs. 41 ±9 mmHg, p = 0.22), the diastolic
pulmonary artery pressure (32 ± 15 vs. 24 ± 6 mmHg, p = 0.38), the pulmonary-to-
Chapter 2 49
60
50
< *0
O-
=S 30
=5 20
10
0
J.,' 20
15
10
5
0
. • ' . : : . • > . i i . ! ! " ' • • • v ' * * ' i '
o
• 0
*8
™ . . . . . . .
1
o
o
8
•i'-Vf!.H
' W-
no yes no
Advanced plexogenic arteriopathy
yes
Figure 2. - Relation between the presence of histologic features of advanced plexogenic
arteriopathy and diastolic PAP (pulmonary artery pressure, mmHg) and PVR (pulmonary vascular
resistance, Wll.m^). • : Autopsy patients; O: Biopsy patients.
systemic pressure ratio (0.81 ± 0.32 vs. 0.58 ± 0.15, p = 0.17), the pulmonary vascular
resistance (10.1 ± 4.7 vs. 7.7 ± 2.2 WU.m^, p = 0.20), and the pulmonary-to-systemic
resistance ratio (0.31 ± 0.18 vs. 0.34 ± 0.13, p = 0.82). Of the histological features
studied, only the presence of plexiform lesions was significantly associated with signs of
persistent pulmonary hypertension. Three out of 5 patients with persistent pulmonary
hypertension showed plexiform lesions, which indicates that the presence of plexiform
lesions has a high positive predictive value (p = 0.02, positive predictive value 100%) for
persistent pulmonary hypertension, but is rather insensitive. The histological classifica-
tion "features of advanced plexogenic arteriopathy" did not correlate significantly with
signs of persistent pulmonary hypertension at follow up (p = 0.26, positive predictive
value 60%).
D I S C U S S I O N ..- - = - o : . . . . - . ; ; . :. <• . . - - ...
The present study demonstrates merely limited correlations between hemodynamic
and histologic assessment of the pulmonary vascular bed in a highly selected group of
children with complex congenital heart disease. Both techniques appeared of limited
value in predicting persistent pulmonary hypertension after corrective surgery at mid-
term follow up. Only plexiform lesions in the lung biopsy were predictive, although
rather insensitive, for persisting pulmonary hypertension. Patients with features of ad-
vanced plexogenic arteriopathy had significantly higher pulmonary artery pressures.
However, the individual variation of the pulmonary artery pressure was wide, hampe-
ring accurate predictions in the individual patient.
Discrepancies between hemodynamic data and structural pulmonary vascular
changes in the individual patient, as frequently found in our patients, are not surprising
if one realizes that the information obtained by both techniques is far from identical.
Histologic examination of lung biopsy is a static description of morphologic vascular
changes, which does not take into account the functional component of the endothe-
lium and smooth muscle cells (16,18,19). On the other hand, hemodynamic data are
derived data, which reflect merely indirect the functional consequences of changes in
the vascular bed. Various assumptions have to be made in calculating flows and resis-
tances, which may result in potential errors (3).
It is believed that patients with early, potentially reversible, stages of pulmonary
plexogenic arteriopathy may develop pulmonary hypertensive crises in perioperative
periods (7). In this study, we have indeed shown that increased muscularity of the
pulmonary tree, expressed as medial hypertrophy, muscularization of arterioles or the
combined total muscularity score, was associated significantly with perioperative
pulmonary hypertensive crises. Preoperative hemodynamic data, however, did not
allow the prediction of perioperative mortality associated with pulmonary hypertensive
crises. Although treatment results have improved with the introduction of vasodilators
like epoprostenol and, more recendy, inhaled nitric oxide, these life-threatening events
continue to lead to significant perioperative mortality.
Assessment of an increased muscularity of the pulmonary tree in an open lung
biopsy can therefore help to identify children at risk for the development of a periopera-
tive pulmonary hypertensive crises. Moreover, the presence of plexiform lesions in an
open lung biopsy was 100% predictive for persistent pulmonary hypertension after
corrective surgery.
A limitation of the present study is that lung biopsies were not performed
routinely, but in patients judged to be at risk for pulmonary vascular disease.
Thirty-one samples were obtained at autopsy. As a result, the patients in this study
represent a highly selected group with a variety of complex cardiac anomalies. Cases
were not classified on the basis of anatomical diagnosis because mechanical forces,
acting on the pulmonary vasculature and resulting from abnormal pulmonary hemody-
namics caused by the anomaly, rather than the anatomical diagnosis itself, are respon-
sible for the initiation of this specific vascular disease process in children with congenital
heart disease.
We conclude that, preoperative hemodynamic data in children with congenital
heart disease are of limited predictive value for perioperative pulmonary hypertensive
crises and for persistent pulmonary hypertension after corrective surgery. Increased
muscularity of the pulmonary arterial tree is associated with perioperative pulmonary
hypertensive crises and plexiform lesions are 100% predictive for persistent pulmonary
hypertension after corrective surgery. . •:.•-•<;<;.': •  -• "
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CHAPTER 3
Pulmonary artery remodeling differs in hypoxia- and
monocrotaline-induced pulmonary hypertension
' f \- «•;•• : - . '
v J U ' X i •'"«Vf ;fc- ' J ' V C ' - . ' ;• ' -
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S U M M A R Y . , „ ••,,.,
In the present study we analyzed structural characteristics of muscular pulmo-
nary arteries and arterioles in two classic models of pulmonary hypertension,
the rat hypoxia and monocrotaline models. We hypothesized that an increase
in medial cross-sectional area would result in reduction of the lumen area and
that these parameters would correlate with the increase in pulmonary artery
pressure (PAP). Four weeks after a single injection of monocrotaline (MCT) or
after four weeks of hypoxic exposure the rats were killed. Both MCT and chronic
hypoxia induced right ventricular hypertrophy. In separate groups of rats both
MCT and chronic hypoxia increased PAP. MCT increased the media cross-
sectional area of pulmonary arteries with an external diameter between 30-100
|xm and 101-200 (im and reduced the lumen area of pulmonary arteries with an
external diameter between 101-200 (im. Chronic hypoxia only slightly in-
creased the media cross-sectional area without a change of the lumen area.
Both MCT and hypoxia increased the percentage of partly muscularized and
muscularized arterioles. The angiotensin converting enzyme (ACE) inhibitor
captopril (0.5 mg/kg/hr) had no effect on MCT-induced pulmonary hyperten-
sion, right ventricular hypertrophy and pulmonary artery remodeling. In
chronic hypoxic rats i t prevented an increase in medial cross-sectional area of
pulmonary arteries with an external diameter between 30-100 urn and attenu-
ated the increase in the percentage of muscularized arterioles, without any ef-
fect on the PAP.
We conclude that MCT, in contrast to chronic hypoxia, induces structural
changes of muscular pulmonary arteries with an external diameter between
101-200 urn which may contribute to an increased PAP and right ventricular
hypertrophy. These data also suggest that angiotensin I I plays a pivotal role in
remodeling of pulmonary arteries in hypoxia but not in MCT-induced pulmonary
hypertension.
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Pulmonary hypertension is a common complication of cardio-pulmonary diseases.
Regardless of the etiology, all patients with chronic pulmonary hypertension have
structural pulmonary vascular changes, right ventricular hypertrophy and, in the long
term, right ventricular failure (1-3). In patients with congenital heart disease, howe-
ver, preoperative hemodynamic findings and postoperative clinical outcome do not
always correlate with structural pulmonary artery changes (4-8). This discrepancy be-
tween hemodynamics and pulmonary artery structure is also true for animal studies.
For example, the angiotensin converting enzyme (ACE) inhibitor cilazapril complete-
ly prevented the thickening of the media of pulmonary arteries in chronic hypoxic rats
but did not decrease the pulmonary artery pressure (PAP) or right ventricular weight
(9). The apparent discrepancies between changes in pulmonary vascular structure and
hemodynamic function may be explained by the fact that vasoconstriction, rather
tlian structural narrowing of pulmonary arteries, plays a pivotal role in the rise of the
PAP. An alternative explanation is that previous studies have focused on the wrong
parameters of structural pulmonary vascular changes. In most studies medial wall
thickness is expressed as a percentage of the arterial external diameter (10-12). This
parameter, however, does not adequately reflect changes in medial cross-sectional area
and lumen area since the external diameter of arteries may also change during the
complex process of vascular remodeling (13). Recently, Mulvany and co-workers in-
troduced an adaptation of terminology to allow a precise description of the structural
changes that can occur in the vasculature (13). The media to lumen ratio and the lu-
men area, rather than medial wall thickness, are essential parameters in this analysis.
In contrast to the systemic circulation, description of structural vascular changes ac-
cording to the concept of Mulvany (14-19) has not yet been employed in the pulmo-
nary circulation. We therefore determined the lumen area, the medial cross-sectional
area and the ratio of media to lumen area of muscular pulmonary arteries with an ex-
ternal diameter between 30-100 and 101-200 urn in two classic rat models of pulmo-
nary hypertension, the rat hypoxia- and monocrotaline models (11, 20, 21). To opti-
mize structural analyses, the pulmonary vessels were fixed under standard
intravascular pressure and maximal vasodilatation. Right ventricular weight and PAP
were measured to correlate structural pulmonary vascular changes with hemodynamic
function. Moreover, we investigated the effects of the ACE inhibitor captopril on pul-
monary vascular remodeling and pulmonary hemodynamics, because angiotensin II
(All) is believed to be involved in hypoxia and MCT-induced pulmonary hypertensi-
on. In both the systemic and pulmonary circulation All acts as a vasoconstrictor and
can induce structural arterial changes like smooth muscle hypertrophy and proliferati-
on as well as matrix protein synthesis (22-26). In animal models of pulmonary hyper-
tension, several ACE inhibitors are known to prevent or attenuate the development of
pulmonary hypertension and medial thickening of pulmonary arteries (9, 27-32).
The consequences of this intervention for the lumen area of pulmonary arteries have,
however, not been described.
Thus we hypothesized that both chronic hypoxia and monocrotaline would
increase the medial cross-sectional area and decrease the lumen area of muscular pulmo-
nary arteries. Second, we hypothesized that changes in the media to lumen ratio and
lumen area of muscular pulmonary arteries would correlate with changes in PAP.
Finally we hypothesized that captopril would prevent or attenuate the reduction of the
lumen area of the pulmonary arteries, right ventricular hypertrophy, and die increase in
PAP in these two rat models.
"sn. .
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M o r p h o l o g i c a l S tud ies ., , . . ; ; . - , . . . .;.•••,,.., ,»-:T^\- , ir i ,r . / . • T
Forty young male Wistar rats (Iffa Credo, Someren, The Netherlands) were used.
Body weight was 145-200 g at the start of the experiments. The rats were randomly
assigned to one of four treatment groups. Food (RMH-TM, Hope Farms, Woerden,
The Netherlands) and water were freely available to all groups of animals. The experi-
ments were performed according to institutional guidelines for the use and care of ani-
mals. All rats were killed four weeks after the start of the experiment.
Group 1: n = 8, AJonocrota/we
At day one these rats received a single subcutaneous injection of monocrotaline
(300(0.1, 60 mg/kg in 0.2N HC1, Sigma, St Louis, MO).
Group 2: n - 8, Wypox/o (WJ
At day one these rats were placed into a normobaric chamber for four weeks. Hypoxic
exposure was accomplished by ventilation with room air (2.5 L/min) and N2
(2.5L/min) resulting in a constant O2 concentration of 10%. The O2 concentration
was checked every day using an O2 analyzer (AVL 993, AVL LIST GmbH, Graz, Aus-
tria). Each day the chamber was opened for approximately 2 minutes to replenish
food and water. . • • ' .! . . ;• • • • • ? ' * . • _ ? • . ; . . . . • :
Group 3: n - 8, Afonocroto/;r;e one/ captopnV
At day one these rats received a single subcutaneous injection of monocrotaline
(300^1, 60 mg/kg in 0.2N HC1). The ACE-inhibitor captopril (0.5 mg/kg/hr in
0.9% NaCl, Sigma) was given for four weeks via osmotic minipumps (Alzet model
2002, Alza Corp., Palo Alto, Ca) implanted subcutaneously between the shoulder bla-
des under ether anesthesia. Before implantation the minipumps were placed in 0.9%
NaCl at 37°C for four hours. After 14 days the minipumps were replaced and a new
pump filled with captopril was inserted at the same site.
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Group 4: n = 8, Wypox/o one/ coptopn'/
These rats were kept under hypoxic conditions for four weeks as described for group
2. During this period the rats received captopril in the same way as described for
group 3.
Group 5: n = 8, Contra/rats (T,) •'-• <- ; =•• -:* > haw-" • u ;•,. . . ,.-• ^
These rats were kept under normoxic conditions (room air) without intervention.
Preparation of lung tissue for morphological measurements '
After induction of anesthesia with sodium pentobarbital (60 mg/kg intraperitoneal-
ly), the right jugular vein was cannulated and the tip of the Silastic canula was positio-
ned into the right atrium. After opening the abdominal wall and the thoracic cavity a
clamp was placed on the inferior caval vein. The abdominal aorta was cut open to al-
low maximal perfusion of the lung vessels. A solution containing phosphate buffered
saline (PBS, pH 7.4) and nitroprusside (1 mg/ml, Sigma) was perfused at a pressure of
18 mm Hg for ten minutes through the pulmonary vessels via the canula in the right
atrium. Subsequently, a solution of 10 % phosphate buffered formalin (pH 7.4) and
nitroprusside (1 mg/ml) was infused for ten minutes for perfusion fixation under
maximal vasodilatation. At the same time 10% phosphate buffered formalin (pH 7.4)
was administered into the lungs via a trachea tube, at a pressure of 20 cm H2O. Subse-
quently, heart and lungs were removed and fixed overnight in 10% phosphate buffe-
red formalin (pH 7.4). Both left and right lung were processed for light microscopy.
The lungs were paraffin embedded and 4 |im sections were stained with Lawson's
stain (Klinipath, Zevenaar, The Netherlands).
Assessment of right ventricular hypertrophy '•
Both atria, the pulmonary trunk, and the aorta were removed from the heart. The
right ventricular wall was separated from the left ventricular wall and ventricular sep-
tum. Wet weight of the right ventricle, free left ventricular wall and ventricular sep-
tum was determined. Right ventricular hypertrophy was expressed as the ratio of
weight of the right ventricular wall (RV) and that of the free left ventricular wall and
ventricular septum (LV+S). •'••••• ^ <
H e m a t o c r i t , .... .- >• •
The hematocrit was determined using a micro capillary centrifuge for five minutes.
After induction of anesthesia with pentobarbital blood samples were drawn from the
orbita.
Light microscopic analysis of pulmonary arteries *ix-<.v«j'.v^-- ,o - ^ *
5
o / p u / m o n a / y o r t e n e s . . , • . • ,« . • >,..—,-, , • . , , . , . , . * < ^ •'
Slides were analyzed by light microscopy by one observer (RJvS) who was unaware of
the treatment group. To assess the type of remodeling of muscular pulmonary arte-
ries, microscopic images were analyzed using a computerized morphometric system
(Quantimet 570, Leica, Cambridge, U.K.). Total vessel area was defined as the area
within the lamina elastica externa and lumen area was defined as the area within the
lamina elastica interna. Medial area is the area between the lamina elastica interna and
die lamina elastica externa. Arteries were categorized depending on the external dia-
meter. Category I included arteries with an external diameter between 30 and 100
|lm, and category II included arteries with an external diameter between 101 and 200
|im. Within each category ten arteries were measured per animal. The average of 10
values obtained were used for calculations. ;, .r i. ;•< ', ,.•; ,.., (.:,.•'; -•.*••'• >,:J.L
Assessment o/ muscu/an'zafr'on o/ arteno/es ' '
Extension of smooth muscle cells into usually nonmuscular arterioles of the alveolar
wall and alveolar duct was assessed as follows. At x400 magnification 100 alveolar wall
and alveolar duct vessels were counted and noted as muscular, partially muscular, or
nonmuscular. These alveolar wall and alveolar duct vessels included small venules
which could not be distinguished from normal pulmonary arterioles. A completely
muscular arteriole was defined as an arteriole with a double elastic lamina for more
than half of its circumference. An arteriole was categorized as partially muscular if the
double elastic lamina was less than half of its circumference. A normal nonmuscular
arteriole had a single elastic lamina. Intra observer variation was 10%., ,.r, , ,...;<•
Hemodynamic Studies
For hemodynamic measurements, separate groups of male Wistar rats (mean initial
body weight 178 gr) were used and treated in an identical way as the rats used for
structural pulmonary vascular analysis (MCT n = 6, MCTcap n = 7, H n = 7, Heap
n = 7, C n = 6).
PAP was measured using the technique described by Rabinovitch and
coworkers (33). In brief, die animals were anesthetized (60 mg/kg pentobarbital,
intraperitoneally) and placed on a heated table (37°C). The trachea was intubated and
the animals were respirated with room air at 60 strokes/min. and 2.5 ml tidal volume.
The right jugular vein was isolated and a stainless steel introducer and catheter were
passed via a small transverse cut. The catheter was connected to a pressure monitor and
was advanced into the right ventricle and pulmonary trunk under guidance of the pres-
sure tracing. With the catheter in place, the introducer was carefully retracted.
Following stabilization during 15 minutes, PAP was recorded during a 15- minute
period using a miniature pressure transducer (CP-01; Century Technology, Ingle-
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wood, CA) and a computerized data-acquisition system (HDAS; Instruments Services
Dept., UM, Maastricht, The Netherlands). Mean pulmonary artery pressure was
calculated by digital integration. .
S t a t i s t i c a l a n a l y s i s •*, • - i " ' ; ^ . . - ; • ? • • * s ' *
Data are expressed as means ± SD. Statistical significance was defined at p < 0.05.
Intergroup differences were evaluated with a non-parametric Mann-Whitney U test
with a Bonferroni correction for multiple group comparison (34). " "^  '•' ~
RESULTS
Morphological Studies
• -t%« •»- V ;• V ^
Body one/ corc//oc
Rats in the control group gained 124 ± 24 g during four weeks. Rats exposed to hy-
poxia or treated with MCT only gained half the weight compared to the control
group. In the MCT group, captopril had no significant influence on the body weight
change (Table 1). In the hypoxic group captopril treatment diminished the gain in
body weight further. The MCT and hypoxic groups exhibited significant right ventri-
cular hypertrophy, defined as an increase of the ratio of right ventricular weight and
the sum of the weight of the left ventricular free wall and interventricular septum
(RV/LV+S ratio) (MCT = 0.69 ± 0.16, H = 0.51 ± 0.09, C = 0.22 ± 0.03, both p <
0.001) compared with the control group. In both groups captopril treatment had no
significant effect on the RV/LV+S ratio. Hematocrit values significantly increased in
the hypoxic rats (H = 72 ± 6, C = 47 ± 2, p < 0.001), whereas the hematocrit signifi-
cantly decreased in the MCT-treated rats (MCT = 42 ± 4, C = 47 ± 2, p < 0.05). Cap-
topril treatment had no effect on the hematocrit (Table 1).
Vessel d imens ions •', •
Catego/y 7 arteries fextemo/ diameter 30-200 |imj
MCT significantly increased the media to lumen ratio (MCT = 46 ± 9, C = 24 ± 4, p <
0.001) and the medial cross-sectional area (MCT = 1,435 ± 344, C = 961 ± 387, p <
0.05) of category I pulmonary arteries. The lumen area showed a trend to decrease alt-
hough this does not reach significant levels (p = 0.2) (Table 2 and Figure 1A and IB).
Hypoxia also increased the media to lumen ratio (H = 38 ± 13, C = 24 ± 4, p = 0.02).
The medial cross-sectional area showed a trend to increase (H = 1,326 ± 410, C = 961
± 387, p = 0.07) whereas the lumen area was not changed. In MCT-treated rats cap-
topril did not effect the media to lumen ratio nor die lumen area. In the hypoxic rats
captopril prevented an increase in the media to lumen ratio (Heap = 28 ± 17, H = 38 ±
Chapter 3
Table 1. - Body weight, heart weight and hematocrit of the five experimental groups.
Group
(n-8)
Control
Monocrotaline
Mono Cap
Hypoxia
Hypoxia Cap
Starting body
weight (g)
193±18
169± 5
174±14
167±15
177±12
Weight
change (g)
+124*24
+ 56±16*
+ 47±21
+ 55±36*
+ 2O±13f
RV
weight (mg)
188±30
383*55*
394±88
354±57*
394*60
RV/BW
(gAg)
0.59±0.08
1.71±0.27*
1.77*0.38
1.61±0.37*
2.00*0.32
LV+S
weight (mg)
846±137
562± 67*
577± 67
691± 92*
736±139
LV/BW
(g/kg)
2.6±0.34
2.4±0.24
2.6±0.30
3.1±0.62
3.7±0.65f
RV/LV+S
0.22*0.03
0.69±0.16*
0.69±0.21
0.51*0.09*
0.54*0.11
Hematocrit
%
47*2
42*4*
42*5
72*6*
76*5
PAP
(mmHg)
15.5*1.5
42.4*10*
36.0*7.
42.7*5.6*
41.0*4.5
(n-6)
(n-6)
(n-7)
(n-7)
(n-7)
All values are means ±SD; n, number of animals per group; RV, right ventricular weight; BW, body weight; LV, left ventricular weight; LV+S, left ventricular!
weight plus septal weight; PAP, pulmonary artery pressure (data from separate groups of rats). * p < 0.05 compared with control group, f p < 0.05 compared!
with hypoxia.
* - * ^
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Figure 1A and B. - Media to lumen ratio (MA/LA) of category I pulmonary arteries in relation to (1A)
the ratio of weight of the right ventricular wall and that of the free left ventricular wall and
ventricular septum (RV/LV+S) and (IB) pulmonary artery pressure (PAP) in control rats (C),
monocrotaline treated rats (MCT), monocrotaline and captopril treated rats (MCTcap), chronic
hypoxic rats (H) and chronic hypoxic and captopril treated rats (Heap). All values are presented as
means. For standard deviations see Tables 1 and 2. * p < 0.05 vs control, f p < 0.05 vs hypoxia.
f 3 I
lame z. - vessel dimensions or muscular pulmonary arteries wren an external diameter Detween
30-200 um.
Cat I (30-100 urn) Cat II (101-200 urn)
Control
MCT
MCTCap
Hypoxia
Lumen area Medial area MA/LA Lumen area Medial area MA/LA
4,146±1,466 96U387 24± 4 17,463±3,601 3,826±1,545 21± 6
3,292± 383 1,435±344* 46± 9* 13,514±1,555* 5,112±l,502* 38±10*
3,225± 899 1,451±326 59±28 16,192±4,119 5,890±l,743 39±18
4,020±l,218 l,326±410 38±13* 18,855±3,977 4,807±l,167 26± 6
Hypoxia Cap 4,180± 528 944±115t 28±17f 20,452±3,045 4,932±l,407 29±19
All values are means ± SD; Cross-sectional lumen and medial area (um*); MA/LA - ratio medial
area to lumen area x 100. *p < 0.05 compared with control group, fp < 0.05 compared with
hypoxia.
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13, p < 0.05) and medial cross-sectional area (Heap = 944 ± 115, H = 1,326 ± 410, p <
0.05). Captopril had no effect on the lumen area. . .. . . „. . (•_ _^
Category 7/ artenes fextema/ rf/ameter 202-200 |
MCT significantly increased die media to lumen ratio (MCT = 38 ±10, C = 21±6, p
< 0.05) and medial cross-sectional area (MCT = 5,112 ± 1,502, C = 3,826 ± 1,545, p
< 0.05) of category II pulmonary arteries whereas die lumen area decreased compared
to control rats (MCT = 13,514 ± 1,555, C = 17,463 ± 3,601, p < 0.05). Hypoxia did
not affect the media to lumen ratio or the lumen area, whereas die medial
cross-sectional area increased to some extent (H = 4,807 ± 1,167, C = 3,826 ± 1,545, p
= 0.07). Captopril treatment had no effect on the media to lumen ratio, medial
cross-sectional area and lumen area neither in MCT-treated rats nor in hypoxic rats
(Table 2).
drterio/es
Both MCT and hypoxia increased the percentage of pardy muscularized and muscu-
larized arterioles and decreased the percentage of nonmuscularized arterioles (Figure
2). In the MCT-treated rats captopril had no effect on muscularization of arterioles,
whereas in hypoxic rats it reduced die percentage of muscularized arterioles and signifi-
candy increased die percentage of pardy-muscularized and nonmuscularized arterioles.
H e m o d y n a m i c S t u d i e s •" • > ' • * * ^ ' ' ^ ^ ' " '•'• "'•' - ' ^ ' * '•' < ^ * ' *•''
M C T and chronic hypoxia induced a significant increase in PAP (MCT = 42.4 ± 1 0
mmHg, H = 42.7 ± 5.6 mmHg, C = 15.5 ± 1.5 mmHg, p < 0.005, Table 1). In bodi
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Figure 2. - The percentage of nonmuscular (NM), partially muscular (PM) and muscular (M) arterioles
in control rats (C), monocrotaline treated rats (MCT), monocrotaline and captopril treated rats
(MCTcap), chronic hypoxic rats (H) and chronic hypoxic and captopril treated rats (Heap). All values
are presented as means ± SD. * p < 0.05 vs control, f p < 0.05 vs hypoxia.
groups captopril did not affect PAP. Captopril treatment had no significant effect on
die PAP in control rats (data not shown).
D I S C U S S I O N '-• '• ' - - • ' v •'•••••••
This is one of the first morphometrical studies of muscular pulmonary arteries, analy-
zed under standard intravascular pressure and maximal vasodilatation, in which
changes of pulmonary artery structure and changes in pulmonary artery pressure arc
compared.
Although the increases in PAP and right ventricular hypertrophy were compa-
rable in the rat hypoxia and MCT model, structural analysis of muscular pulmonary
arteries reveals major differences between the two models which may be due to the way
we analyzed die pulmonary vascular structure. In general, structural pulmonary
vascular changes in animal models of chronic pulmonary hypertension include thick-
ening of the media of muscular pulmonary arteries and muscularization of normally
nonmuscular arterioles. Some studies have shown diat chronic hypoxia and MCT
induce different patterns of pulmonary vascular remodeling. Muscularization of arteri-
oles is seen in both models, however, medial hypertrophy of muscular pulmonary
arteries is more extensive in monocrotaline treated rats (35, 36). Only a few studies
report the consequences of these structural vascular changes for the lumen diameter
(11,20,37). These investigators stated that thickening of the wall of pulmonary arteries
contributed to a decrease in the lumen diameter. Changes in lumen diameter, however,
were based on arteriograms and were investigated without maximal vasodilatation.
Thus vasoconstriction rather than structural vascular changes may have been respon-
sible for the reported reduction of the lumen diameter. To exclude the possible effects of
vasoconstriction on medial cross-sectional area and lumen area, we performed
morphometrical analysis of pulmonary arteries after maximal vasodilatation and fixed
the vessels /« «<w at standard intravascular pressures. By this way we are assured that an
increase in medial cross-sectional area indeed reflects a structural increase of the medial
cross-sectional area rather than active pulmonary vasoconstriction. Moreover, in those
conditions a reduction of the lumen area reflects a structural reduction rather than a func-
tional reduction of the lumen area as a consequence of pulmonary vasoconstriction.
Under these conditions MCT increased the medial cross-sectional area and
media to lumen ratio of pulmonary arteries with an external diameter between 30-100
Hm and 101 -200 (X m. The consequences for the lumen area, however, were different in
these two categories of pulmonary arteries. As expected, an increase in medial cross-
sectional area was associated with a reduction of the lumen area of pulmonary arteries
with an external diameter between 101 -200 |im. The lumen area of pulmonary arteries
with an external diameter between 30-100 (im did, however, not change. This indicates
that the type of pulmonary vascular remodeling in MCT-induced pulmonary hyper-
tension differs in different segments of the pulmonary arterial tree.
In contrast to MCT, hypoxia only slightly increased the medial area and did not
alter the lumen area of pulmonary arteries with an external diameter between 30-200
Jim. Several studies have shown a significant increase in media thickness of muscular
pulmonary arteries in chronic hypoxic rats whereas we only showed a trend to an
increase of the medial cross-sectional area (20,38). We assume that, in those studies in
which pulmonary arteries were studied without fixation under standard intravascular
pressure and without maximal vasodilatation, a significant part of the media thickening
can be attributed to active pulmonary vasoconstriction rather than a structural increase
in media thickness. Previous studies have shown that the development of an increase in
the PAP and media thickening of pulmonary arteries differs in the hypoxia and MCT
model (11,20). Hypoxia induces a significant increase in the PAP and media thickness
after 3 days, whereas in MCT-treated rats significant changes in the PAP and media
thickness were observed after 21 days. In these studies the level of PAP correlated with
the degree of arterial wall thickness. The present study shows differences of pulmonary
anery remodeling, not only between the two models but also in different segments of
the pulmonary artery tree. This suggests that different mechanisms other than pressure
contribute to pulmonary artery remodeling.
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These structural pulmonary vascular changes, such as an increase in medial
cross-sectional area and a reduction of the lumen area in MCT-treated rats, correlate
well with an increased PAP and right ventricular hypertrophy. Although chronic hy-
poxia also increased the PAP and induced right ventricular hypertrophy, the medial area
only slighdy increased in absence of changes of the lumen area. As stated earlier, vaso-
constriction rather than structural vascular changes of muscular pulmonary arteries may
contribute to hypoxia-induced pulmonary hypertension. Structural vascular changes of
anerioles rather than small sized muscular pulmonary arteries could provide an alterna-
tive explanation for hypoxia-induced pulmonary hypertension as hypoxia increased the
number of muscularized and partially muscularized arterioles. Hypoxia-induced poly-
cythemia, however, could be a confounding factor, because an increase in blood viscosi-
ty contributes to an increase in pulmonary vascular resistance (39).
Previous studies have demonstrated that ACE inhibitors can at least partially
prevent the development of MCT and hypoxia-induced pulmonary hypertension and
structural pulmonary vascular changes (9, 27-32). In die present study the ACE
inhibitor captopril did not prevent the MCT-induced increase in medial mass of
muscular pulmonary arteries, had no effect on the lumen area, and did not reduce the
percentage of muscularized arterioles. Moreover, captopril did not prevent MCT-
induced increase in PAP and right ventricular hypertrophy. We therefore believe that
angiotensin II (All) is an unimportant modulator of structural pulmonary vascular
changes in this model. This hypothesis is supported by a previous report of Cassis who
showed that the specific nonpeptide All type 1 receptor antagonist, Losartan, could not
prevent MCT-induced PAP and structural pulmonary vascular changes (10).
In contrast to the lack of effect in MCT-treated rats, captopril prevented the
increase in medial cross-sectional area of pulmonary arteries in chronic hypoxic rats and
reduced the percentage of muscularized arterioles. This effect was, however, without a
decrease in PAP or right ventricular hypertrophy. From this observation we conclude
that the effect of captopril on the pulmonary vascular structure is a direct one and not
due to an effect on pulmonary hemodynamics.
There may be several explanations for the inability of captopril to reduce PAP and
right ventricular hypertrophy despite its potential to prevent an increase in medial
cross-seaional area and reduce the percentage of muscularized anerioles. As previously
stated, one possibility is diat die increased blood viscosity due to polycythemia is respon-
sible for the increased PAP and right ventricular hypertrophy, as captopril had no effect
on the increased hematocrit in chronic hypoxic rats. Another possibility is that, despite a
significant reduction of die percentage of muscular arterioles in captopril treated hypoxic
rats, die percentage of muscularized and partially muscularized arterioles is still signifi-
cantly increased compared to control rats (Figure 2). The vascular tone of these
muscularized and partially muscularized arterioles may, even under normoxic condi-
tions, still be increased and therefore contribute to a sustained increased PAP (40).
One of the limitations of this study is that we did not analyze the lumen area of
arterioles because it is technically impossible to perform on these small vessels the type
of morphometrical analysis that was performed on muscular arteries. To optimize
morphometrical analysis of pulmonary anery dimensions we compared pulmonary ar-
teries with approximately the same external diameter. Within each experimental group
we therefore analyzed two categories of pulmonary arteries (30-100 and 101 -200 |i.m),
with comparable median external diameters between the groups.
In conclusion, this study demonstrates that the type of pulmonary artery remod-
eling in chronic hypoxic and MCT-treated rats is heterogeneous, not only between the
groups but also in different segments of the pulmonary arterial tree. Moreover, these
data suggest that All plays a role in hypoxia but not in MCT-induced pulmonary artery
remodeling. Finally, we showed that morphometric analysis of structural changes of
muscular pulmonary arteries, in the rat hypoxia and MCT models of pulmonary hyper-
tension, under optimal conditions only reveals a limited correlation between changes in
pulmonary artery structure and changes in pulmonary artery pressure. Other factors
like vasoconstriction or structural vascular changes at the level of arterioles may play a
more important role in the increase in pulmonary artery pressure.
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CHAPTER 4
Dissociation of pulmonary vascular remodeling and
right ventricular pressure in tissue ACE-deficient
mice in conditions of chronic alveolar hypoxia
cmjuq to ror*s«
iGJuD'
r b r i r v ; r<r 9 3 r m
S U M M A R Y
The present study was designed to characterize the effects of chronic hypoxia
on pulmonary vascular remodeling and its functional consequences in tissue
ACE-deficient mice. Based on the data obtained by pharmacological inhibition
of ACE in rats we hypothesized that under chronic hypoxic conditions tissue
ACE-deficient mice show less remodeling of pulmonary aiterioles as compared
to wild-type mice, but have equally increased right ventricular pressures.
Wild-type and tissue ACE-deficient mice were exposed to chronic hypoxia for 4
weeks. Under normoxic conditions the percentages of non-muscular, partially
muscularized and completely muscularized aiterioles as well as the mean right
*"* ventricular pressure and right ventricular weight were comparable in wild-type
72 and tissue ACE-deficient mice. Under chronic hypoxic conditions the percent-
age of completely muscularized aiterioles was lower in tissue ACE-deficient
mice compared to wild-type animals (20.4 ± 7.9 vs 36.2 ± 11.6%, p < 0.01),
whereas the percentage of partially muscularized aiterioles had increased
(51.7 ± 11.5 vs 40.8 ± 5.6%, p < 0.05). The mean right ventricular pressure and
the extent of right ventricular hypertrophy were not different in chronic hy-
poxic wild-type and tissue ACE-deficient mice. We conclude that pulmonary
vascular remodeling, but not mean right ventricular pressure is attenuated in
chronic hypoxic tissue ACE-deficient mice compared to chronic hypoxic wild-
type littermates.
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Chronic alveolar hypoxia is associated with the development of pulmonary hyperten-
sion and right ventricular hypertrophy. Both hypoxia-induced vasoconstriction and
structural pulmonary vascular changes contribute to an increased pulmonary artery
pressure. Hypoxia-induced structural pulmonary vascular changes include increased
medial thickness of small muscular pulmonary arteries and peripheral extension of
smooth muscle cells into normally non-muscular arterioles, commonly called pulmo-
nary vascular remodeling (1,2). These structural changes are a result of vascular
smooth muscle cell proliferation, hypertrophy and deposition of extracellular matrix
components (3-6). In the systemic circulation angiotensin II (All) has been shown to
be a mediator of vascular smooth muscle cell growth and/or proliferation (7-9) and
may therefore also be seen as a potential modulator of the structural pulmonary vascu-
lar changes associated with pulmonary hypertension. During the development of hy-
poxic pulmonary hypertension local ACE expression is increased in the walls of small
pulmonary arteries (10). Most All is produced in the lungs through the conversion of
Angiotensin I into All by angiotensin I-converting-enzyme (ACE) at the membrane
of endothelial cells. Several studies have investigated the effects of ACE inhibitors on
pulmonary artery pressure and pulmonary artery structure under normoxic and chro-
nic hypoxic conditions. Under normoxic conditions ACE inhibition has no effect on
rat pulmonary artery pressure and pulmonary artery structure (11,12). Most studies
report that in chronic hypoxic rats ACE inhibitors prevent or attenuate the develop-
ment of pulmonary artery medial thickening and/or muscularization of arterioles
(12-14). The literature is, however, less clear on the effects of ACE inhibitors on pul-
monary artery pressure. In chronic hypoxic rats it has been shown that the ACE inhi-
bitor cilazapril completely prevents medial thickening of pulmonary arteries without
a significant effect on pulmonary artery pressure and right ventricular weight (15).
Data from our group show that the ACE inhibitor captopril prevented an increase in
medial cross-sectional area of small (30-1 OOflm) muscular pulmonary arteries in chro-
nic hypoxic rats and reduced the percentage of muscularized arterioles (16). This ef-
fect occurred, as in the study by Clozel and co-workers (15), without a decrease in pul-
monary artery pressure or right ventricular hypertrophy. Others, however, did report
a preventive effect of ACE inhibition on the increase in pulmonary artery pressure du-
ring hypoxia (12-14).
Recently, tissue ACE-deficient mice have been generated by introducing a
modified ACE allele into a mouse line (17). Mice homozygous for this mutant allele
(~/_) have significant plasma ACE activity, but no tissue-bound enzyme. They also have
a low systemic blood pressure, renal vascular thickening, and a urine concentrating
defect. There are no data available on the pulmonary vasculature although this mouse
strain provides an excellent tool for studying the role of tissue ACE in the development
of pulmonary vascular remodeling and pulmonary hypertension under chronic
hypoxic conditions. Based on the data in rats (16) we hypothesized that under
* * • I • f-Ti;»;\,
normoxic conditions tissue ACE-deficient mice have a normal pulmonary artery pres-
sure and no structural pulmonary vascular changes under normoxic conditions. Under
chronic hypoxic conditions, however, they show less remodeling of arterioles compared
to wild-type mice, yet pulmonary artery pressure increases to a comparable extent as in
hypoxic wild-type mice. ,; ,, ; . . -•_• .--;^,,,.,;•• • ^ •. ,1 - ; i .. .
METHODS ,;.:•..:.,
Experimental animals
We studied mice with a targeted disruption of the ACE gene (homozygous mutant
("/_)) on a C57BL/6J genetic background and wild-type (+/J littermates. Male and
female mice with an age of 6-10 weeks, weighing 18 to 30 g were used for the experi-
ment. The generation of these mice has been described by Esther and co-workers (17).
They were a gift from Dr. Bernstein (Atlanta, Georgia, USA). At an age of 21 days the
offspring was weaned and genotyped by PCR analysis (18). Animals were provided
food (RMH-TM; Hope Farms, Woerden, The Netherlands) and water ad libitum
and were maintained on a 12-hour light/dark cycle. The experiments were performed
* according to institutional guidelines for the use and care of animals and approved by
& the local ethical committee. All mice were killed 4 weeks after the start of die experi-
u m e n t . •;_ ,, • . ,-,• . n . . . , > • ; ; . . . ; • • ! j ! / ( > y v ; t _• a o ; . •>• . •;
E x p o s u r e t o c h r o n i c h y p o x i a , I ; ., :>•; «,->••.;,. . . . , ,: ' - ; ••;
At day 1 mice were placed into a normobaric chamber for 4 weeks. The chamber was
maintained at 10% O2, which was accomplished by controlling die inflow rates of
room air and nitrogen. The O2 concentration was checked every day using an O2 ana-
lyzer (AVL 993, AVL LIST GmbH, Graz, Austria). Each day the chamber was ope-
ned for approximately 1 minute to replenish food and water.
E x p e r i m e n t a l g r o u p s . , . ,. .'.,.; ..-,. , , .; -^,. .•,..,_•..,.-
A total of 41 mice were investigated. Wild type ( V J and tissue ACE-deficient (~/_)
mice were studied under normoxic (~/_ n = 8; */+ n = 11) and chronic hypoxic (~/_ n =
10; */+ n= 12) conditions. Groups were matched for age and gender, t >/» r-••• r,'i..f>••:••.
H e m o d y n a m i c s tudies : • .i . W J . - . S . - ] ; , . : . = • : . • •
At the end of the experiment the mice were anesthetized (110 mg/kg pentobarbital,
intraperitoneally, Sanofi Sante B.V., Maassluis, The Netherlands) and placed on a
heated table. The trachea was intubated, and the lungs were ventilated with room air
Chapter 4 75
at 80 strokes/min and 1.5 ml tidal volume. A parasternal thoracotomy from the xip-
hoid to the pretracheal region was performed. A needle (outer diameter 0.6 mm) con-
nected to a silastic tube was placed into the right ventricular cavity by direct puncture
of the right ventricle. The tube was connected to a pressure monitor. Following stabi-
lization for 10 minutes, the right ventricular systolic and diastolic pressures were re-
corded during a 10-min period using a miniature pressure transducer (CP-01); Cen-
tury Technology, Inglewood, CA) and a computerized data-acquisition system
(HDAS; Instruments Services Dept., Maastricht University, Maastricht, The Nether-
lands). Mean right ventricular pressure (MRVP) was calculated by digital integration.
Assessment of right ventricular hypertrophy £' jbt-.*?'
The heart was dissected free and both atria, the aorta and the pulmonary trunk were
removed. The right ventricle was separated from the left ventricle and the ventricular
septum. Right ventricular hypertrophy was expressed as the ratio of the weight of the
right ventricular wall (RV) and that of the left ventricular wall and ventricular septum
(LV+S). -
• • • • • . - . • • • , - ' „ • • • . J f V i r :• i " ! » H : • : > - i ^ . - . : . i i . - { j i t : ; ; - j v . . , < . , i • I & . ' J J J J ! - - l a , j . ' i . - j j ,
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After induction of anesthesia with pentobarbital, blood samples were obtained from
an orbita puncture. The hematocrit was determined using a micro capillary centrifuge
for five minutes. ••..-•••': - )
Assessment of muscularization of arterioles ' • ' ' '
After the hemodynamic studies 10% phosphate-buffered formalin (pH 7.4) was infu-
sed into the lung via a trachea tube, at a pressure of 20 cm H2O. Subsequently the he-
art and lungs were excised and fixed for 24 hours in 10% phosphate-buffered formalin
(pH 7.4). Both lungs were paraffin embedded and 4-(im sections, parallel to the hilus,
were stained with a monoclonal antibody against a-smooth muscle actin (DAKO, di-
lution 1:500) using Diaminobenzidine as the chromogen and hematoxylin as the
counter stain (19).
Atx 400 magnification 50 alveolar wall and alveolar duct vessels were counted,
and the proportion of muscularized and partially muscularized vessels was calculated
and recorded as a percentage of the total alveolar wall and alveolar duct vessels. A
completely muscularized arteriole was defined as an aneriole with a-smooth muscle
actin-positive cells forming a subendothelial layer of more than 50% of its circumfer-
ence. A partially muscularized arteriole was defined as an arteriole where a-smooth
muscle actin-positive cells formed a subendothelial layer of less than 50% of its circum-
ference. If a-smooth muscle actin staining was absent, the vessel was termed
n o n m u s c u l a r . T h i s analys is w a s p e r f o r m e d b y a s ing le o b s e r v e r (RJvS) w h o w a s
u n a w a r e o f t h e e x p e r i m e n t a l c o n d i t i o n s . . , , ., ,..,... .--,-,•<,,-,,.,-.;: .--..p
S t a t i s t i c a l a n a l y s i s > , ...;,.,.•....-, , .. , . •, . . . < . , ; • . . . • , , , , - , W : > H ^ , , ^ - . .
All results were expressed as means ± SD. Differences between groups were determi-
ned using a non-parametric Mann-Whitney U test with a Bonferroni correction for
multiple group comparison (20). Statistical significance was defined at p < 0.05.
RESULTS . . - . ; -v - ... -H • - - 10 * , ; • - , > ; , t
Cardiac weights ,;. , - , , . ; > . , ^;Um&D'v •
Under normoxic conditions right ventricular weight and the ratio of right ventricular
weight to body weight was comparable in wild-type and tissue ACE-deficient mice. In
both wild-type and tissue ACE-deficient mice chronic hypoxic conditions induced
right ventricular hypertrophy. The extent of right ventricular hypertrophy did not
differ between wild-type and tissue ACE-deficient hypoxic mice (Table 1).
* The mean weight of the LV+S was lower in both normoxic and hypoxic tissue
1x ACE-deficient mice compared to normoxic and hypoxic wild-type mice (normoxia ~/_
5 = 87 ± 7.7 mg, normoxia */+ = 114 ± 17 mg, p < 0.01; hypoxia "7_ = 103 ± 28 mg,
76 hypoxia */+ = 135 ± 20 mg, p < 0.01). The ratio of the LV+S/BW, however, was not
different between tissue ACE-deficient mice compared to wild-type mice (normoxia
"/_ = 3.8 ± 0.2, normoxia •/«. = 4.3 ± 0.6; hypoxia "/_ = 5.2 ± 1.0, hypoxia +/+ = 5.8 ± 0.8).
Because the mean right ventricular weights in normoxic tissue ACE-deficient and
wild-type mice were also comparable, the higher ratio of RV/LV+S in tissue
ACE-deficient mice is mainly due to their lower LV+S (normoxia */+ = 0.23 ± 0.03 vs
normoxia "/_ = 0.28 ± 0.05, p < 0.05). .... ,; ,.,-, ,v., ...JI,,*,•<*.
Hematocrit
In wild-type mice hypoxia caused hematocrit values to increase from 41 ± 3.7% to 70
± 5.5% (p < 0.01). Also in tissue ACE-deficient mice hypoxia caused an increase in
hematocrit values from 39 ± 2.9% to 62 ± 6.2% (p < 0.01). The hematocrit in hy-
poxic, but not in normoxic wild-type mice, was higher than the hematocrit in hypoxic
tissue ACE-deficient mice (70 ± 5.5 vs 62 ± 6.2%, p < 0.05).
Normoxia
Hypoxia
7-
V-
(n)
(11)
(8)
(12)
(10)
(9)
R«
weight (mg) (mg/g) weight (mg)
27.4±6.1 25.2±1.9
23.2±2.7 24.6±3.8
0.97±0.2
1.08±0.2
114±17
87±7.7f
23.U2.6 58±13.5* 2.5 ±0.5* 135+20
19-9*3.6 49±14.2* 2.4WU- JJJSf
LV+S/BW
4.3±0.6
3.8±0.2
5.8±0.8*
5.2±1.0*
RV/LV+S
(mg/g)
0.23±0.03
0.28±0.05f
0.44±0.1*
0.48±0.1*
Hematocrit
%
41±3.7
39±3
70±5.5*
62±6.2*f
MRVP
(mmHg)
7.1±1.3
9.3±0.9f
12.7±1.8*
12.2±2.0*
- ^
NM C Z I PM
100
Figure 1. - The percentage of non-muscular (NM), partially muscularized (PM) and completely
muscularized (M) arterioles in wild-type (*/+) and tissue ACE-deficient ("/.) normoxic and hypoxic
mice. All values are presented as means ± SO. *p < 0.05 compared with genotype-matched normoxic
mice, t P < 0.05 compared with wild-type mice with the same exposure.
Pulmonary vascular morphology .:
Aformox/a . : - . « -
Under normoxic conditions the percentage of nonmuscular, partially muscularized
and completely muscularized arterioles was not significantly different between
wild-type and tissue ACE-deficient mice (Figure 1).
Chronic hypoxia decreased the percentage of nonmuscular arterioles in both
wild-type and tissue ACE-deficient mice (hypoxia */«. = 22.9 ± 12.5%, normoxia */+ =
60.9± 16.2%, p< 0.01; hypoxia-/_ = 27.9 ± 11.9%, normoxia -/_ = 48.5 ± 10.9%,
p < 0.01) (Figure 1). The percentage of completely muscularized arterioles increased
in both wild-type and tissue ACE-deficient chronic hypoxic mice compared to nor-
moxic mice (hypoxia */+ = 36.2 ± 11.6%, normoxia +/+ = 4.8 ± 5%, p < 0.01; hypoxia
~/_ = 20.4 ± 7.9%, normoxia ~/_ = 7 ± 3%, p < 0.01), but the percentage completely
muscularized arterioles was lower (~/_ = 20.4 ± 7.9% vs */+ = 36.2 ± 11.6%, p < 0.01)
and the percentage of partially muscularized arterioles was higher ("/_ = 51.7 ± 11.5%
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vs +/+ = 40.8 ± 5.6%, p < 0.05) in chronic hypoxic tissue ACE-deficient mice compa-
red to chronic hypoxic wild-type mice. Thus hypoxia-induced pulmonary vascular re-
modeling is attenuated in tissue ACE-deficient mice. ' : ^ -.-ifjin««',w*-i»-nr
H e m o d y n a m i c s t u d i e s ' ^ ' v « ' ' '••* • < • • / ' ••••- • • • •. - ••.•••,••••''••-• - " • ' • ' •••"-"• • « . • " • • - ^
The mean right ventricular pressure (MRVP) in normoxic tissue ACE-deficient mice
was slightly higher compared to normoxic wild-type mice (normoxia ~7_ = 9.3 ± 0.9 vs
normoxia +/+ = 7.1 ± 1.3 mmHg, p < 0.01). MRVP in bodi wild-type and tissue
ACE-deficient hypoxic mice was increased compared to genotype matched normoxic
mice (hypoxia +/+ = 12.7 ± 1.8 vs normoxia */+ = 7.1 ± 1.3 mmHg, p < 0.01; hypoxia
-/_ = 12.2 ± 2.0 vs normoxia~/_ = 9.3 ± 0.9 mmHg, p < 0.05) (Table 1). There was no
difference in MRVP between wild-type and tissue ACE-deficient hypoxic mice (*/+ =
12.7 ± 1.8 vs-/_ = 12.2 ± 2.0 mmHg).
D I S C U S S I O N - ' - ^ . " . v : . ' • * * - • ' • • > ( ; » ; > : - « - ; « ' ; ; , . - . w ! . ; , , :•-•:,.' ..• - • ••:• v , n • ; •
In the present study we compared hemodynamic and structural pulmonary vascular
changes in wild-type and tissue ACE-deficient mice under normoxic and chronic hy-
poxic conditions. The major finding of this study is that pulmonary vascular remode-
ling is attenuated in hypoxic tissue ACE-deficient mice compared to hypoxic
wild-type littermates. The data suggest that, in mice, local production of All by ACE
in pulmonary arterioles plays an important role in pulmonary vascular remodeling se-
cundary to chronic hypoxia. The residual structural pulmonary vascular changes in
tissue ACE-deficient mice is probably due to the activity of plasma ACE, which is re-
duced (30%) but not absent in these mice. Experiments performed in hypoxic rats
corroborate with these findings. Morrell and co-workers have demonstrated that ACE
expression is increased in small pulmonary arteries of rats with hypoxia-induced pul-
monary hypertension (10). Moreover, several studies have shown that ACE inhibitors
can at least partially prevent the development of hypoxia-induced structural pulmo-
nary vascular changes (1 l,13,15)most probably via inhibition of pulmonary vascular
smooth muscle cell proliferation and/or growth (12), an effect that is angiotensin type
1 receptor mediated (21) and apparently pressure independent (16).
Another interesting result of the present study is that the mean right ventricular
pressure and the extent of right ventricular hypertrophy was not different in wild-type
and tissue ACE-deficient hypoxic mice despite a significant reduction of completely
muscularized arterioles in tissue ACE-deficient hypoxic mice. This result is in accor-
dance with the results from a previous study from our group in which we demonstated
that the ACE inhibitor captopril also attenuated the increase in the percentage of
completely muscularized arterioles, without any effect on the pulmonary artery pres-
sure and right ventricular hypertrophy in chronic hypoxic rats (16). A possible explana-
tion for the dissociation between structural changes of arterioles and right ventricular
pressure is that other structural changes like medial thickening of muscular pulmonary
arteries (external diameter between 30-200|lm) contribute to an increase in MRVP. In
rats, we have shown that chronic hypoxia only slightly increased the media cross-
sectional area without a change of the lumen area (16) suggesting that neither changes
in media cross-sectional area nor lumen area are significant contributors to hypoxia-
induced pulmonary hypertension. In the mouse lung, the number of these muscular
pulmonary arteries suitable for morphometrical analyses is too low to allow reliable
measurements with respect to total vessel area, medial area and lumen area. Another
explanation for the dissociation between arteriolar structure and right ventricular pres-
sure could be the fact that despite a significant reduction of the percentage of
completely muscularized arterioles in hypoxic tissue ACE-deficient mice, the
percentage of partially muscularized arterioles was significantly increased compared to
hypoxic wild-type mice. Constriction of these partially muscularized arterioles may,
even under normoxic conditions, obscure potential effects of a reduced percentage of
completely muscularized arterioles on the MRVP and right ventricular hypertrophy.
Since the mean right ventricular pressure and the extent of right ventricular
hypertrophy was comparable in wild-type and tissue ACE-deficient hypoxic mice, it is
unlikely that right ventricular All formation plays a crucial role in the development of
right ventricular hypertrophy secondary to hypoxia-induced pulmonary hypertension.
This would argue against the suggestion of Morrell and co-workers that locally
increased right ventricular ACE activity and expression may play a role in the patho-
genesis of right ventricular hypertrophy secondary to hypoxic pulmonary hypertension
(22).
Hematocrit levels were increased in hypoxic wild-type mice as compared to
hypoxic tissue ACE-deficient mice. It is, however, unlikely that a difference in the
hematocrit between wild-type and tissue ACE-deficient hypoxic mice obscures a
potential effects of a reduced percentage of completely muscular arterioles on the
MRVP and right ventricular hypertrophy. First of all Steudel and coworkers have
shown that in hypoxic mice, even a very high hematocrit (65-75%) does not impose
sufficient additional work load on the right ventricle to cause hypertrophy (23).
Moreover, normalization of the data for hematocrit would result in a lower MRVP in
hypoxic tissue ACE-deficient mice compared to wild-type hypoxic mice.
An unexpected observation was a slightly higher MRVP in normoxic tissue
ACE-deficient mice compared to normoxic wild-type mice. This is in contrast with our
hypothesis based on previous studies that have shown that in rats under normoxic
conditions ACE inhibition has no effect on pulmonary artery pressure (11,12). The
mechanism resulting in a higher MRVP in normoxic tissue ACE-deficient mice is
unclear. It is known that tissue ACE-deficient mice have a low systemic blood pressure
(17). It is, however, unlikely that the higher MRVP in tissue ACE-deficient mice is
secondary to left ventricular failure because the cardiac output in these mice is compa-
rable with wild-type mice (W. Aartsen, personal communication).
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In summary, rhis study demonstrates that pulmonary vascular remodeling is
attenuated in hypoxic tissue ACE-deficient mice compared to hypoxic wild-type litter-
mates which implies that local production of All by ACE in pulmonary arterioles plays
an important role in the pathogenesis of pulmonary vascular remodeling secundary to
chronic hypoxia, but not in hypoxia-induced pulmonary hypertension. Local All
formation does not seem to play a crucial role in the development of right ventricular
hypertrophy. . , , .
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CHAPTER 5
The DD genotype of the angiotensin converting
enzyme gene is negatively associated with right
ventricular hypertrophy in male patients with
chronic obstructive pulmonary disease
• • - " ' i j • . . • » . .
S U M M A R Y
The renin angiotensin system plays an important role in the development of
pulmonary artery remodeling and right ventricular hypertrophy in hypoxia-
induced pulmonary hypertension as may occur in patients with COPD. Several
polymorphisms of genes encoding for components of the renin angiotensin
system such as the M***T polymorphism in the angiotensinogen gene, the
287-base-pair insertion ( I ) /delet ion (D) polymorphism atintron 16 of the ACE
gene and the A"**C polymorphism in the angiotensin I I type 1 receptor gene
have been associated with an increased risk of cardiovascular diseases. With
respect to the pulmonary circulation, only limited data exist on possible asso-
ciations between polymorphisms of these genes and pulmonary hypertension
and/or right ventricular hypertrophy. The objective of the present study was to
investigate a possible relationship between polymorphisms of the renin angio-
tensin system and electrocardiographic evidence of right ventricular hypertro-
phy in patients with COPD. We therefore determined the angiotensinogen
(M*^T), angiotensin converting enzyme (I/D), and angiotensin I I type 1 re-
ceptor (A ' " 'C) genotypes in 87 patients with severe COPD and correlated
these data with electrocardiographic parameters of right ventricular hypertro-
phy. Thirty-one patients (36%) of 87 patients with COPD showed electrocardio-
graphic evidence of right ventricular hypertrophy. In the male, but not in the
female subgroup, the angiotensin converting enzyme DD genotype was nega-
tively associated with electrocardiographic evidence of right ventricular hyper-
trophy (male: x* - 3.8, p - 0.05, female: x^ - 0.05, p - 0.82). We found no as-
sociations between the investigated polymorphisms in the angiotensinogen
and angiotensin I I type 1 receptor genes and electrocardiographic evidence of
right ventricular hypertrophy.
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INTRODUCTION -.-s, ??
The development of pulmonary hypertension in patients with chronic obstructive
pulmonary disease (COPD) is associated with hypoxia-induced pulmonary vasocon-
striction and pulmonary vascular remodeling (1). Recent studies suggest that the ren-
in angiotensin system plays an important role in the development of both pulmonary
artery remodeling and right ventricular hypertrophy in hypoxia-induced pulmonary
hypertension. In rats, angiotensin converting enzyme (ACE) expression is increased in
the walls of small pulmonary arteries and in the right ventricle during the develop-
ment of hypoxia-induced pulmonary hypertension (2, 3). Moreover, in several animal
models of hypoxia-induced pulmonary hypertension ACE inhibitors and angiotensin
II type 1 receptor (AGTjR) antagonists attenuate or prevent the development of
structural pulmonary artery changes and right ventricular hypertrophy (4-7). In pa-
tients with COPD most investigators report a significantly higher serum ACE activity
and plasma renin activity than in normoxic-normocapnic subjects (8,9). Plasma ACE
levels are also known to be elevated in subjects homozygous for the deletion allele
(DD) of the ACE gene compared with heterozygotes (ID) or subjects homozygous for
the insertion (II) allele (10, 11). The ACE DD genotype has been associated with a va-
riety of cardiovascular diseases such as left ventricular hypertrophy, increased risk of
myocardial infarction, cardiomyopathy, and coronary artery disease (11-15). Also,
polymorphisms in other genes of the renin angiotensin system such as the M ^ T po-
lymorphism in the angiotensinogen (AGT) gene and the A ^ ^ C polymorphism in
the angiotensin II type 1 receptor (AGTjR) gene have been associated with cardiovas-
cular disease such as essential hypertension, coronary heart disease, and myocardial in-
farction (16-20). With respect to the pulmonary circulation, only limited data exist
about an association between pulmonary hypertension, right ventricular hypertrop-
hy, right ventricular function, and polymorphisms of the renin angiotensin system.
One study reports that the ACE DD genotype is more prevalent in patients with pri-
mary pulmonary hypertension than the non-DD genotype (21). Although the degree
of pulmonary hypertension was comparable, patients with the ACE DD genotype
had a preserved cardiac output, a lower pulmonary vascular resistance, and lower right
atrial pressures than did patients with the non-ACE DD genotype. This finding cau-
sed the investigators to suggest that the ACE DD genotype may permit the develop-
ment of more extensive adaptive right ventricular hypertrophy in patients with prima-
ry pulmonary hypertension and may be seen as a marker of maintained right
ventricular function. Associations between the M ^ T polymorphism of the angio-
tensinogen gene or the A^ '^C polymorphism of the angiotensin II type 1 receptor
gene and pulmonary hypertension have not been described. Also the extent to which
these polymorphisms may contribute to the development of right ventricular hyper-
trophy in patients with COPD is unknown. Therefore we determined the distributi-
on of polymorphisms of the ACE gene (I/D), AGT,R gene (A' ^ C ) , and AGT gene
235 in patients witii severe stable COPD and correlated these data with electro-
•n
!
cardiographic parameters of right ventricular hypertrophy. In analogy with the fin-
dings of Abraham and co-workers (21) and data derived from the systemic circulation
we hypothesized that, also in patients with COPD, the ACE DD, AGTjR CC, and
the AGT TT genotype were positively correlated with right ventricular hypertrophy.
M E T H O D S . ....... , . , , ; ,. , . , ..,,,: • . . - , . • , , ; & • , ; , , „ • , . - : • ' • > , - > <
Study Popu la t i on ,• •, - • ! i , ^ . .
The study group consisted of 87 patients with COPD (62 male, 25 female), ranging
from 46 to 79 yr of age (mean, 65 yr), who were admitted to the pulmonary rehabili-
tation centre Hornerheide (Horn, The Netherlands). COPD was diagnosed in all pa-
tients according to the criteria of the American Thoracic Society (22), and FEVi was
expressed as a percentage of the reference values (FEVj% pred) < 70% (23). All pa-
tients were stable at the time of the study. Patients with electrocardiographic evidence
of severe left ventricular hypertrophy anoVor myocardial infarction and patients with
signs of left ventricular heart failure and/or heart murmers on physical examination
were excluded. The research program was approved by the local ethical committee,
and informed consent was obtained from all patients. . ••;,,. -•-.'•'
Control Group
86
The control group consisted of 95 subjects (42 male, 53 female) 41 to 70 yr of age
(mean, 50 yr). They had no clinical history of C O P D and a FEVj % pred within nor-
mal limits (mean FEV] % pred, 9 3 % ; SD, 8) and were, as the study group, all Cauca-
sians and living in the same region. : ' • . . ....,_•; ;i.»ii'F iVftj y.%r)'-- ••-••'>;••.. '•
Pulmonary Function and Blood Gas Studies .-.,•.•• ,, r,,- .,• , ; -iD:.»n.t:.!.-j n •
was measured, using the pneumotachograph (Masterlab; Jaeger, Wurzburg,
Germany). Values were expressed as a percentage of reference values. For arterial
blood gas analysis blood was obtained by puncture of the radial artery while patients
breathed room air. The Pao2> PacO2> «md S*O2 were measured using a blood gas ana-
lyzer (ABL 330; Radiometer, Copenhagen, Denmark). ,, ....,,, .....
Electrocardiography ,-....,„ ,; ;., . • , , ; • ; , , : - , ; , > / > ••-. - : , -,.•; <:,^,:r --,
To assess the presence of right ventricular hypertrophy a 12-lead electrocardiogram
(ECG) was made. The following ECG criteria of right ventricular hypertrophy were
used: (1) Incomplete or complete right bundle branch block. (2) Right axis deviation,
defined as a frontal plane QRS axis of > 90 degrees. (3) P wave in lead VI , II, or III of
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> 2.5 mm (P pulmonale). (4) S wave of > 1.5 mm in lead I in combination with a slow
R progression. (5) Clockwise rotation of the heart in the horizontal axis defined as a
shift in the transition zone to V5 or beyond. (6) Low voltage QRS complex of < 5 mm
in all the limb leads (II, III, and AVF).
The ECGs were evaluated by two cardiologists (PvP and EC). In all patients
agreement was reached. A positive ECG diagnosis suggestive for right ventricular
hypertrophy was accepted if two or more ECG criteria were present (24).
E x t r a c t i o n a n d A m p l i f i c a t i o n o f G e n o m i c DNA ..• -- < , . , ? . - ?<?
Genomic DNA was extracted from peripheral blood leukocytes with the QIAmp
Blood Kit (QIAGEN Inc. Chatsworth, CA).
j4Cf/>o/)'worp/;w7w. The ACE genotype was determined by the polymerase
chain reaction (PCR) and subsequent gel electrophoresis of the PCR products using the
method described by Rigat and colleagues (25). All DD genotypes were subjected to a
second, independent PCR amplification to avoid mistyping in ID heterozygote
subjects in which the I allele is sometimes suppressed (26). This second PCR did not
identify any mistyping.
Y4(JF//? />o/y»20^Att;w. The A ' ^ C polymorphism was determined by PCR
amplification of genomic DNA according to the method described by Bonnardeaux
and colleagues (18).
-^GT/w/yrao^/ww. The M - ^ T variant was analyzed after PCR amplification
of genomic DNA and restriction digestion with Tth 111 I as described by Russ and
colleagues (27).
. f e ' > ; • ; ? < • N - 0 ' ; "' > . H ' : • • • • ' •*••• •'•' • f r i ^ ; i • • ; . : •
Statistical Analysis . . • • • ; • ,;
Differences in genotype distributions between patients with COPD and without clcc-
trocardiographic evidence of right ventricular hypertrophy were tested by the
chi-square test (x^)- Means of variables potentially related to the development of right
ventricular hypertrophy were compared by two-sample f test. Statistical significance
was defined at p < 0.05 (28). The Statistical Package for Social Sciences (release 7.5;
SPSS Inc., Chicago, IL) was used for statistical analyses.
R E S U L T S v , . , - , , . . , , , . ! , , . , . •.•u-.-s/i.- . . j f c . V . T - • , - . . < ! . - ' v . : ! V - i : . - - - V ? -;!•• ™..
Pulmonary Function Test and Blood Gas Analysis
The mean FEVj (% pred) was 37% (range 16 to 70%). The mean Paco2 and Pao2
were 5.7 kPa (range 4.1 to 8.7) and 9.3 kPa (range 6.3 to 12.7) respectively. The mean
Sao2 was 93.3% (range 80 to 98%).
Ti
H e m a t o c r i t a n d A g e . — . ; : •... •..-, •• " * . - . . :-: T . : •<.-•». ^ .» . N » : - . - I ^ T '
The mean Ht was 43.3% (range, 33 to 52%). The mean age was 65 yr (range, 46 to 79
yr)-
• i : r , • . . r- . • • « i •• - - - • ? • • •• " ; : - • ' o . - . T
M e d i c a t i o n .. •; - . .•.' • : . <•• •' ; . j ; ' , s t > ,:,.•.</ ;;:•-/... >„
Patients receiving antihypertensive drug treatment (ACE inhibitors [n = 8], angioten-
sin II receptor blockers [n = 1 ], or calcium antagonists [n = 10]) were equally distribu-
ted over the different genotypes and patients with or without right ventricular hyper-
trophy.
Electrocardiographs Evidence of Right Ventricular Hypertrophy ;>}•. ..
Thirty-one patients (36%) of the entire study group of 87 patients had electrocardiog-
raphic evidence of right ventricular hypertrophy. Fourteen patients (16%) showed
two criteria, nine patients (10%) showed three criteria, five patients (6%) showed four
criteria, and three patients (4%) showed five criteria of right ventricular hypertrophy.
F r e q u e n c i e s o f R A S G e n o t y p e s i n t h e S t u d y G r o u p ' , ... i . • , • • „_ . , . , . • , - , . , <
The distribution of the DD, ID, and II genotypes of the angiotensin converting enzy-
me gene was 32, 49, and 19%, respectively. The distribution of die AA, AC, and CC
genotypes of the angiotensin type 1 receptor gene was 53, 37, and 10% respectively,
and the distribution of the MM, MT, and TT genotypes of die angiotensinogen gene
was 33, 49, and 18% respectively. £"V<^'A ;•"'.: >-J- ~=
Frequencies of RAS Genotypes in the Control Group , - , . . ; •; '
j * • i!
The distribution of the DD, ID, and II genotypes of the angiotensin converting enzy-
me gene was 29, 53, and 18%.The distribution of the AA, AC, and CC genotypes of
die angiotensin type 1 receptor gene was 42, 49, and 9% respectively, and the distri-
bution of the MM, MT, and TT genotypes of the angiotensinogen gene was 33, 48,
and 19% respectively. These percentages did not significandy differ from patients
with COPD (p = 0.96, 0.33, and 0.97, respectively).
Separate analysis of frequencies of RAS genotypes in male and female subgroups
in the study group and the control group did not significandy differ eidier (data not
shown).
. •• ! > • "
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Table 1 . - Association between right ventricular hypertrophy and the ACE DO or non-DD geno-
type.
ACE GENOTYPE RVH X* P Odds ratio 95%CI
Yes(%) No(%)
All patients (n-87) _ _ _ _ ^ _
DD(n-27) 22.2 77.8 J.U U.UU 1.8 0.8-4.0
non 00 (ID, II) (n-60) 41.7 58.3
Male patients (n-62)
DD(n-19) 21.1 78.9 3.8 0.05 2.2 0.8-5.5
non DD (ID, II) (n-43) 46.5 53.5
Female patients (n-25)
DD(n-8) 25 75 0.05 0.82 1.1 0.2-4.8
non DD (n-17) 29.4 70.6
Zte/fm'ftbn o/abfcrew'afrbns: n - number of patients; ACE - angiotensin converting enzyme; RVH -
right ventricular hypertrophy; CI - confidence interval.
Associations between the ACE genotypes and right ventricular hypertrophy
In the male subgroup, the ACE DD genotype was negatively associated with electro-
cardiographic evidence of right ventricular hypertrophy ( j ^ = 3.8; odds ratio, 2.2;
95% confidence interval, 0.8 to 5.5; p = 0.05) (Table 1). In the female subgroup there
was no such association ( j^ = 0.05; odds ratio, 1.1; 95% confidence interval, 0.2 to
4.8; p = 0.82). There was no association between the presence of the D allele (DD and
ID) and the presence or absence of electrocardiographic evidence of right ventricular
hypertrophy (entire study group: X^  = 0.56, p = 0.45; male: X^ = 0.38, p = 0.53; fema-
le: %2 = 0.05, p = 0.82).
Possible Confounding Variables in ACE I/D Genotype Subgroups
Mean Paco2> P«*O2 *"^ S*O2 were comparable between the different subgroups (for
instance, DD versus non-DD: Paco2 = 5 6 and 5.7 kPa, respectively, Pao2 = 9.1 and
9.3 kPa, respectively, (Table 2). Patients (male and female) with the DD genotype
had a significant higher Ht than did patients with the non-DD genotype (mean, 44.7
and 42.7%, respectively, t = -2.9, p = 0.004). This was also true in the male subgroup
with the DD genotype (mean, 45.1 and 42.9%, respectively, t = -2.6, p = 0.01). Pa-
tients with the D allele (DD and ID) were significantly younger than the patients with
the II genotype (mean, 64.7 and 67.8 yr, respectively, t = 1.9, p = 0.05) and had a sig-
Table 2. - Mean values of possible confounding variables between the ACE 00 and non-DD geno-
type in male, female patients and the entire study group*.
Age (yr)
FEV, (%pred)
P a ^ (kPa)
Pa<,2 (kPa)
Sa<,2 (%)
Ht (%)
Male and female
DD
64.1± 6.6
38.2±12.7
5.6± 0.7
9.1± 1.3
93.2± 3.1
44.7± 2.6
non-DD
65.9± 7.3
36.8±12.2
5.7± 0.8
9.3± 1.2
93.4± 2.8
42.7± 3.4f
Male
DD
64.6 ± 7.7
36.2 ±10.5
5.5 ± 0.7
9.2 ± 1.1
93.5 ± 2.2
45.1 ± 2.8
non-DD
66.6± 7.1
35.2±12.6
5.8± 0.9
9.3± 1.1
93.4± 2.8
42.9± 3.4i
Female
DD
62.8± 3.0
43.7±17.0
5.7± 0.8
8.8± 1.7
92.3± 5.2
43.8± 2.2
non-DD
64.1± 7.6
40.7±10.7
5.5± 0.7
9.3± 1.4
93.2± 2.9
42.1± 3.7
0e/?nrtio/7 o/oftbreWafron: yr - years; Ht - hematocrit. * All values are means ± SD. f p < 0.004
compared with DD group. } p < 0.01 compared with DD group.
nificantly higher FEVj (% pred) than did patients with the II genotype (mean, 38.5
and 31.7%, respectively, t = -2.2, p = 0.03).
Associations between the AGTjR and AGT Genotypes and Right Ventricular
Hypertrophy
90 We found no significant associations between the investigated polymorphisms in the
AGT i R and AGT genes and electrocardiographic evidence of right ventricular hyper-
trophy, neither for the group as a whole nor for female and male subgroups.
Poss ib l e C o n f o u n d i n g V a r i a b l e s i n A G T j R a n d AGT G e n o t y p e S u b g r o u p s ; •<-
Mean PacO2> P*O2 and FEV] (% pred) were comparable between the different sub-
groups (data not shown). Male patients with the AGTjR C allele (CC and AC) had a
significantly lower SaQ2 and were significantly older than the patients with the
AGTiR AA genotype (mean Sao2 92.7 and 94.1%, respectively, t = 2.0, p = 0.04 and
mean age, 68 and 64 yr, respectively, t = -2.1, p = 0.03). This was also true for the
mean age in the entire group (mean age, 67 and 64 yr, respectively, t = -1.9, p = 0.05).
DISCUSSION , -p " : r . i -« - , - : ->« - ; i :./ ;; . . ^ « H ~ « s ^
The main finding of this study was a negative association between the ACE DD geno-
type and electrocardiographic evidence of right ventricular hypertrophy in male pa-
tients with COPD. This negative association was in contrast with our hypothesis that
stated that the ACE DD genotype would be positively associated widi right ventricu-
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lar hypertrophy. This hypothesis was based on recent findings of Abraham and collea-
gues (21) in patients with pulmonary hypertension that indeed showed more extensi-
ve adaptive right ventricular hypertrophy. An important difference, however, between
those data and our study is that Abraham and coworkers studied patients with prima-
ry pulmonary hypertension, whereas we studied patients with COPD who may deve-
lop pulmonary hypertension secondary to chronic alveolar hypoxia. The different
outcome of the two studies may suggest that the function of the renin angiotensin sys-
tem differs in primary pulmonary hypertension from that in secondary pulmonary
hypertension in COPD. A differential function of the renin angiotensin system was
also observed in two different animal models of pulmonary hypertension (7).
Because we realize that the prevalence of right ventricular hypertrophy in
patients with COPD increases not only with the severity of airway obstruction but also
with several other factors such as age, hypoxemia, CO2 retention, and polycythemia
(29,30), we analyzed the effects of these possible confounding variables on the associa-
tions between ACE genotypes and electrocardiographic evidence of right ventricular
hypertrophy. The mean Paco2> P^O2, FEVj (% pred), SaQ2> and age were not signifi-
cantly different in patients with the DD genotype from those in patients with the
non-DD genotype. However, the mean Ht was significantly higher in both the patient
group as a whole and in the male subgroup with the DD genotype compared with the
non-DD genotype patients (mean, 44.7 and 42.7%; mean, 45.1 and 42.9%, respec-
tively). The higher hematocrit reported for the whole patient group with a DD geno-
type versus patients with the non-DD genotype may be explained by the higher
hematocrit in the male subgroup. Although these mean Ht values are within normal
limits and the mean differences are small, the increased Ht could potentially contribute
to increased pulmonary arterial pressures in patients with COPD with the DD geno-
type. However, an increased Ht would be associated with an increased right ventricular
hypertrophy. Because we found a negative association between the ACE DD genotype
and right ventricular hypertrophy, normalization of the data for Ht would result in an
even stronger negative association between the ACE DD genotype and right ventric-
ular hypertrophy.
The ACE DD genotype was negatively associated with right ventricular hyper-
tophy, but only in the male patients. Interestingly, the ACE DD genotype was recently
found to be a sex-specific candidate gene for systemic hypertension (31), albeit that in
that study the ACE DD genotype was positively associated with systemic hypertension.
In female patients no association was found between the DD genotype and elec-
trocardiographic evidence of right ventricular hypertrophy. It is well known that the
female sex is a cardioprotective factor, and there is a growing body of evidence that
estrogens modulate the development of cardiac hypertrophy (32). Estradiol protects
against pulmonary vascular remodeling and right ventricular hypertrophy in male
monocrotaline treated rats (33). Finally, estradiol treatment has been shown to
attenuate hypoxia-induced vasoconstriction in lamb lungs (34). We therefore believe
that, although most female patients in this study were postmenopausal, estrogens may
mask or delay a potential association between the ACE genotype and right ventricular
hypertrophy in female patients with COPD.
Patients carrying the D allele (DD and ID) were significantly younger and had a
significantly higher FEV[ (% pred) than did patients with the II genotype. Younger age
and a higher FEV i (% pred) could theoretically mean less right ventricular hypertrophy
compared with older patients and patients with a lower FEVj (% pred). In the present
study, however, there was no association between the presence of the D allele (DD and
ID genotype) and the presence or absence of electrocardiographic evidence of right
ventricular hypertrophy.
No significant associations were found between the angiotensin II type 1
receptor (A'"^C) and angiotensinogen ( M ^ T ) genotypes and electrocardiographic
evidence of right ventricular hypertrophy. In the systemic circulation, the angiotensin
II type 1 receptor CC genotype and especially the angiotensinogen TT genotype have
been associated with essential hypertension (18, 19). The data presented here suggest
that these polymorphisms do not significantly contribute to the development of
pulmonary hypertension and/or right ventricular hypertrophy in patients with COPD.
In theory, the distribution of RAS genotypes may be different in patients with
COPD from that in patients without COPD. However, the distributions of the ACE,
AGT]R, and AGT genotypes found in the present study did not significantly differ
" from those in our control group and those described in control populations of other
B. studies (12, 17, 20). It is therefore unlikely that the negative association between the
£ DD genotype of the ACE gene and electrocardiographic parameters of right ventricular
32 hypertrophy is influenced by differences in ACE genotype distribution in patients with
and without COPD. The mean age of the control group was 50 yr (SD, 7), which is
indeed lower than the mean age of the COPD group (65 yr; SD, = 7). To exclude a
possible pre-COPD confounder in the control group we have subanalyzed the data of
the control group. Analysis of the RAS genotypes in the older subjects in the control
group (mean age, 58 yr; SD, 5; n = 27) did not reveal a significant change in genotype
distribution, not when compared with the young subgroup (mean age, 45 yr; SD, 3; n =
68; FEV] % pred = 94%; SD, 7), or when compared with the COPD group. Moreover,
mean FEVi% pred in that older subgroup of our control population was 90% (SD, 8),
which is not significantly different from the 93% (SD, 8) of the total group, and far
above that in the COPD group (37%). Therefore, we think that it is very unlikely that
our control group contained a COPD-prone subpopulation.
A limitation of the present study was that evidence of right ventricular hyper-
trophy was based on electrocardiographic criteria. Although electrocardiography is
highly specific for detecting right ventricular hypertrophy in patients with COPD, this
technique is rather insensitive (35).
In conclusion, this study has shown a negative association between the ACE DD
genotype and electrocardiographic evidence of right ventricular hypertrophy in male
patients with COPD. This may indicate that male patients with COPD with the ACE
DD genotype have lower mean pulmonary arterial pressures and in theory have a better
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prognosis than do male patients with the non-DD genotype. On the other hand it
could mean that male patients with COPD with the ACE DD genotype show less adap-
tive right ventricular hypertrophy, which theoretically could mean a worse prognosis
when compared with male patients with the non-DD genotype. Further studies that
include hemodynamic and echocardiographic measurements are needed to elucidate
whether this negative association is a result of lower mean pulmonary arterial pressures
or diminished adaptive right ventricular hypertrophy in these patients. Analysis of
polymorphisms of the ACE gene may, in the future, play an important role in the risk
assessment and medical management of pulmonary hypertension in male patients with
COPD.
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CHAPTER 6
Endothelial nitric oxide synthase gene
polymorphisms and right ventricular hypertrophy in
patients with chronic obstructive pulmonary disease
ic ;..
nr yiqov^&qyd isknirinev jr!r>n n;tn e'^lfiqion^k •_
S U M M A R Y
Nitric oxide (NO) contributes to the maintenance of low pulmonary vascular
tone in healthy humans and there is evidence to suggest that changes in NO
production play a role in the pathogenesis of pulmonary hypertension in pa-
tients with chronic obstructive pulmonary disease (COPD). The G894T polymor-
phism in exon 7 of the eNOS gene has been reported to be a strong risk factor
for coronary spasm, acute myocardial infarction and essential hypertension,
• whereas the 27-bp repeat polymorphism in intron 4 of the endothelial nitric
•§, oxide synthase (eNOS) gene contributes to the variance of basal NO produc-
£ tion. There are, however, no reports on an association between the above men-
~TT tioned polymorphisms of the eNOS gene and right ventricular hypertrophy in
patients with COPD. We correlated electrocardiographic parameters of right
ventricular hypertrophy with these two polymorphisms of the eNOS gene in 86
patients with severe stable COPO. 35% of these patients showed electrocardio-
graphic evidence of right ventricular hypertrophy. No association was found
between the investigated polymorphisms of the eNOS gene and electrocardio-
graphic evidence of right ventricular hypertrophy in patients with severe stable
COPO. In the present study we found no association between the eNOS T or a al-
leles and electrocardiographic evidence of right ventricular hypertrophy in pa-
tients with severe stable COPD.
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Nitric oxide (NO) is a potent vasodilator and contributes to the maintenance of low
pulmonary vascular tone in healthy individuals (1-3). NO is synthesized from
L-arginine by nitric oxide synthase (NOS). Three isoforms of NOS have been identi-
fied: the neuronal constitutive nitric oxide synthase (nNOS), the inducible nitric oxi-
de synthase (iNOS) and the endothelial constitutive nitric oxide synthase (eNOS),
which is expressed in normal pulmonary endothelial cells. A reduction in basal NO
release may predispose to the development of pulmonary hypertension and there is in-
creasing evidence to suggest that alterations of eNOS expression in the lung may play
a role in the pathogenesis of hypoxia induced pulmonary hypertension as occurs in pa-
tients with COPD. Indeed several authors have reported that endotheli-
um-dependent relaxation is impaired in pulmonary arteries of patients with COPD
(4,5). The data on the expression of the eNOS gene are however less clear. Both decre-
ased (6) and increased (7) expression of eNOS have been reported in patients with pri-
mary and secondary pulmonary hypertension. Also experimental studies have yielded
some contradictory data with respect to NOS mRNA expression under hypoxic con-
ditions. Hypoxia decreases the expression of eNOS mRNA in human pulmonary en-
dothelial cells (8), whereas increased expressions of nNOS, eNOS and iNOS
mRNA's have been reported in the rat lung under hypoxic conditions (9-11). In mice
with a congenital deficiency in the eNOS gene hypoxic pulmonary vascular remode-
ling, pulmonary hypertension and right ventricular hypertrophy is enhanced as com-
pared with wild-type animals (12). These latter data suggest that the production of
NO by eNOS may provide a counterbalance against hypoxia induced pulmonary va-
soconstriction.
There are several possibilities to explain the contradictory data with respect to
eNOS expression and pulmonary hypertension. One of those is the effect of the
guanine (G) to thymine (T) substitution polymorphism of the eNOS gene (G894T)
within exon 7 resulting in a replacement of glutamic acid by aspartic acid at codon 298
(Glu298Asp). The functional consequences of this G to T substitution are not known
yet, but the missense Glu298Asp variant has been reported to be a strong risk factor for
coronary spasm, acute myocardial infarction and essential hypertension (13-16). A
27-bp repeat polymorphism is another variant of the eNOS gene. A recent study in
healthy individuals indicates that the 27-bp repeat polymorphism of the eNOS gene
contributes to the variance of basal NO production (17). The gene encoding eNOS is
located on chromosome 7q35-36. In the fourth intron two alleles have been identified
that differ by one 27 base pair repeat. The eNOS a allele has four repeats and the eNOS
b allele has five repeats. For both polymorphisms no data are available for a possible
association with right ventricular hypertrophy in patients with COPD. With respect to
the eNOS G/T polymorphism we hypothesized that, in analogy with data derived from
the systemic circulation, the eNOS T allele in patients with COPD is positively associ-
ated with right ventricular hypertrophy. With respect to the eNOS a/b polymorphism
the hypothesis was that in patients with COPD, the eNOS a allele is beneficial, because
the higher level of basal NO production in these patients may counterbalance the
hypoxia induced pulmonary vasoconstriction. This would mean that patients with
COPD and the eNOS a allele have lower pulmonary artery pressures compared with
the eNOS bb genotype and as a consequence show less adaptive right ventricular hyper-
trophy. Since there are no data available with respect to a potential association of the
G/T and a/b polymorphisms of the eNOS gene and pulmonary hypertension associ-
ated right ventricular hypertrophy in patients with COPD we correlated electrocardio-
graphic parameters of right ventricular hypertrophy with the distribution of eNOS
GG, GT, TT, aa, ab and bb genotypes in patients with severe stable COPD.
M E T H O D S . . ,• . . . , - = .
S t u d y P o p u l a t i o n , i • - <•>, ~" , * ;.-•>•
Eighty-six patients with severe COPD were included in this study (61 male, 25 fema-
le) with a mean age of 65 years (range 46-79 years). Informed consent was obtained
from all patients, and the research program was approved by the local ethical commit-
" tee. All patients had COPD according to the criteria of the American Thoracic Socie-
'§. ty (18) and FEVj expressed as a percentage of the reference values (FEV]% pred) <
£ 70% (19). Patients were admitted to the pulmonary rehabilitation centre Hornerhei-
IQQ de (Horn, the Netherlands) and were stable at the time of the study. Patients with
electrocardiographic evidence of severe left ventricular hypertrophy and/or myocardi-
al infarction and patients with signs of left ventricular heart failure and/or heart mur-
mers on physical examination were excluded.
Control Group .
The control group consisted of 95 individuals (42 male, 53 female) without a clinical
history of COPD. The mean FEVj% pred was 93% (SD, 8).The mean age was 50 ye-
ars (range 41-70 yr) These individuals were, as the study group, all Caucasians and li-
ving in the same region.
Pulmonary Function and Blood Gas Studies , : .
FEV] was measured, using a pneumotachograph (Masterlab; Jaeger, Wurzburg, Ger-
many) and expressed as a percentage of reference values (FEVj % pred.). Blood was
drawn by puncture of the radial artery while patients breadied room air. PaQ2> PacO2>
and Sao2 were measured using a blood gas analyzer (ABL 330; Radiometer, Copenha-
gen, Denmark).
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E l e c t r o c a r d i o g r a p h y " " "•'"' ' ' ; * ' " ^
A 12-lead electrocardiogram (ECG) was made to assess the presence of right ventricular
hypertrophy. The following ECG criteria of right ventricular hypertrophy were used:
1. Incomplete or complete right bundle branch block. 2. Right axis deviation,
defined as a frontal plane QRS axis of > 90°. 3. P wave in lead VI, II or III of >2.5 mm
(P pulmonale). 4. S wave of >1.5 mm in lead I in combination with a slow R progres-
sion. 5. Clockwise rotation of the heart in the horizontal axis defined as a shift in the
transition zone to V5 or beyond. 6. Low voltage QRS complex of < 5 mm in all the limb
leads (II, III, andAVF).
The ECGs were evaluated by two cardiologists (PvP and EC) and in all patients
agreement was reached. A positive ECG diagnosis suggestive for right ventricular
hypertrophy was accepted if two or more ECG criteria were present (20).
Genotyping of the G894T Polymorphism in Exon 7 of the eNOS Gene
Genomic DNA from peripheral blood leukocytes was extracted with the QIAmp
Blood Kit (QIAGEN Inc. Chatsworth, California, USA). We adopted the mutageni-
cally separated PCR technique (21) to determine the genotype of the G894T mutati-
on. Briefly, two allele-specific primers and their nonselective complementary strand
primer were mixed and used for the PCR amplification in a single reaction. Deliberate
differences were introduced into the allele-specific primers in addition to the base sub-
stitution, and they were able to drastically reduce cross-reactions between two allelic
PCRs in a mixed reaction. The following primers were used: FP894T,
5'-AAACGGTCGCTTCGACGTGCACCCCCTGCTGCTGCAGGCCCCAGA
TGGI-3 ' ; FP894G, 5'-TGCCCCTGCTGCTGCAGGCCCCAGATIAG-3';
RP894, 5'-TGTGGGATCAGCACCCCCTTGCAGGCCC-3', in which delibera-
ted differences and base substitutions are underlined. PCR was performed in a 25 |ll
reaction volume containing 50 mmol/L KC1, 10 mmol/L Tris-HCl pH 8.3, 2
mmol/L MgCl2,0.1 mmol/L each of the four dNTPs, 5 pmol of primer FP894T, 10
pmol of primer FP894G, 10 pmol of primer RP894, and 1.25 U AmpliTaq® DNA
Polymerase (Perkin Elmer Inc.). The initial denaturation for 5 minutes at 94°C was
followed by 40 cycles, each of94°C for 45 seconds, 64°C for 45 seconds, and 72°C for
45 seconds, and by a final extension at 72°C for 10 minutes. The size of PCR products
was 180 bp and 200 bp for the 894G and 894T alleles, respectively, which were resol-
ved on a 3% agarose gel.
Genotyping of the 27-bp Repeat Polymorphism in Intron 4 of the eNOS Gene
DNA was extracted as described above. The eNOS a/b genotype was determined by
the polymerase chain reaction (PCR) and subsequent gel electrophoresis of the PCR
products according to the method described by Wang (22).
Sta t i s t i ca l Analysis v ; H • - . . : • '
The Hardy-Weinberg equilibrium for the frequencies of the two eNOS genotypes
and differences in genotype distributions between patients with COPD with and wit-
hout electrocardiographic evidence of right ventricular hypertrophy were tested by
the chi-square analysis (x^)- Means of variables potentially related to the development
of right ventricular hypertrophy were compared by a two-sample f test. Statistical sig-
nificance was defined at p < 0.05 (23). The Statistical Package for Social Sciences
(SPSS Inc., release 7.5, Chicago, IL) was used for statistical analyses.
RESULTS , , ... . . ;-,„. ,„. . , , ; ,„: ,•.-: «
Allele Frequencies
Allele frequencies in both control and patient populations were in Hardy-Weinberg
equilibrium.
Pulmonary Function Test and Blood Gas Analysis and Hematocrit in Patients
with COPD
|
5 The mean FEVj (% pred) was 37% (range 16 to 70%). The mean Paco2
J02 were 5.7 kPa (range 4.1-8.7) and 9.3 kPa (range 6.4-12.7) respectively. The mean
Sao2 was 93.5% (range 80-98%).The mean Ht was 43.3% (range 33-52%).
: • , ; • • > • - . • ' . • • . ; . • • • : • . • • " • " ' . ' : i ' ^ ^ ' • • - • • •
Medication ,' — , • . • • •'• •, . , ; f sv ! ' : ; - -
• . • . • • . • . - ^ r / . • . > ' T > • ' • . . - • • . , :
Pa t ients receiving ant ihyper tens ive d r u g t r ea tmen t ( A C E inhib i tors [n = 8 ] , ang io ten-
sin II receptor blockers [n = 1], r ca lc ium antagonis ts [n = 10]) were equally d is t r ibu-
ted over the different genotypes and pa t ien t s w i t h or w i d i o u t r ight ventr icular hyper-
t rophy . -',',• -., . I ' -? , M-rik -.-••' )- ' •'. -J ••• !'.fi.-- '•• ^ :;'••.-:'. -,-i,/ ,'..;/,;,-•;
Elect rocard iograph ic Evidence o f R igh t Vent r icu la r Hyper t rophy ,;•• ,-^  ; •••• •':
Thirty patients (35%) of the entire study group of 86 patients showed electrocardiog-
raphic evidence of right ventricular hypertrophy. Fourteen patients (16.3%) showed
two criteria, nine patients (10.5%) showed three criteria, five patients (5.8%) showed
four criteria, and two patients (2.3%) showed five criteria of right ventricular hyper-
trophy. .
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; Table 1. - Association between right ventricular hypertrophy and the eNOS a/b and G/T genotype.
eNOS GENOTYPE
eNOS a/b (n-86)
a allele (aa, ab) (n-28)
bb (n-58)
eNOS G/T (n-86)
TT (n-5)
non TT (N-81)
T allele (TT, GT) (n-47)
GG (n-39)
RVH
Yes (%)
39.3
33.3
20.0
35.8
36.2
33.3
No (%)
60.7
66.7
80.0
64.2
63.8
66.7
X'
0.29
0.51
0.07
P
0.5
0.4
0.7
Odds ratio
0.8
1.7
0.9
95%CI
0.4-
0.3-
0.5-
•1.5
•10.5
•1.6
Definition o / aMretaotibns: n - number of patients; RVH - right ventricular hypertrophy; CI -
confidence interval.
Frequencies of eNOS G/T Genotypes in Patients with COPD and the Control
The genotype frequencies for eNOS GG, GT, and TT in patients with COPD were
45.3 (n = 39), 48.8 (n = 42) and 5.8% (n = 5) respectively. In the control group the
distribution of the GG, GT and IT genotypes of the eNOS gene was 48.4,40.0, and
11.6%. These percentages did not significantly differ from patients with COPD (x^ =
2.5; p = 0.2). The frequencies of eNOS G/T genotypes in the male and female sub-
groups of patients with COPD and the controls did not significantly differ either
(data not shown). ...<. .. . , . . ... ,.
Associations Between the eNOS G/T Genotype and Right Ventricular
H y p e r t r o p h y !•. : . ; . • • • - • . - . ; : > . , • . r . • • ; • „ . . ,
There was no association between the presence of the eNOS T allele and the presence
or absence of electrocardiographic evidence of right ventricular hypertrophy, neither
in homozygous (TT) nor in homozygous and heterozygous group of patients (TT and
GT) (x* = 0.51; p = 0.4 and X^  = 0.07; p = 0.7 respectively; Table 1).
Possible Confounding Variables in the eNOS G/T Genotype Subgroups ••; • i
Mean age, FEV] (% pred) Paco2> PaO2> Sac>2 *"d hematocrit were comparable be-
tween patients with COPD with the eNOS TT genotype compared with patients
Table 2. - Mean values of possible confounding variables between the different genotypes of the
eNOS gene.
a allele bb TT non-TT T allele GG
Age (yr)
FEV, (%pred)
Pacoz (kPa)
Paoz (kPa)
Saoz {%)
Ht(%)
65.5± 6.7
36.9±12.8
5.8±
9.5±
94.1±
43.0±
0.9
1.0
1.5
2.8
65.2± 7.5
37.4±12.3
5.6±
9.2±
93.2±
43.5±
0.7
1.2
3.0
3.6
66.4±9.7
41.4±8.1
5.3±0.6
8.1±0.8
91.4±2.1
42.0±5.7
65.2± 7.0
36.9±12.5
5.6±
9.3±
93.4±
43.4±
0.8
1.2
2.9
3.2
65.6± 7.3
38.3±12.9
5.6±
9.2±
93.1±
43.7±
0.8
1.2
2.9
3.9
64.8± 7.0
35.8±11.5
5.6±
9.4±
93.6±
42.8±
0.8
1.2
2.9
2.5
Oc/fm'tion o/fl66rew'otfon: yr - years; Ht - hematocrit. All values are means ± SO.
with the non-TT genotype (GT and GG) and patients with the presence of the T alle-
le (TT and GT) compared with patients with the GG genotype (Table 2).
Frequencies of eNOS a/b Genotypes in Patients with COPD and in the Control
Group
5 The genotype frequencies of eNOS aa, eNOS ab, and eNOS bb in patients with
f COPD were 1.2 (n = 1), 31.4 (n = 27), and 67.4% (n = 58) respectively. In the control
»-» group the distribution of the aa, ab and bb genotypes of the eNOS gene was 4.2,28.4,
104 and 67.4% respectively. These percentages did not significantly differ from patients
with COPD (x^ = 1.6; p = 0.43). The frequencies of eNOS a/b genotypes in the male
and female subgroups of patients with COPD and the controls did not significandy
differ either (data not shown). ,
Associat ions Between the eNOS a /b Genotype and Right Ventr icular »«•*-.:.;;••
Hypertrophy
Only one patient had the eNOS aa genotype. In the statistical analysis this patient was
included in the patients group with the eNOS ab genotype (presence of an a allele).
There was no association between the presence of the eNOS a allele and electrocardi-
ographic evidence of right ventricular hypertrophy, neither in the group as a whole
nor in the female and male subgroups (group as a whole: X^ = 0.29; p = 0.5, female
subgroup: X^  =0.12; p = 0.7, male subgroup: X^ = 0.22; p = 0.6; Table 1). ; • > "
Possible Confounding Variables in the eNOS a/b Genotype Subgroups >•" - • • -
Mean age, FEV] (% pred) Paco2> Pa<)2> S*O2 *"^ hematocrit were comparable be-
tween patients with COPD with the presence of the a allele (aa and ab genotype) com-
pared with patients with die eNOS bb genotype (Table 2).
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DISCUSSION ^ ^ . H t i
In contrast with our hypothesis we found no association between the eNOS T or a al-
leles and electrocardiographic evidence of right ventricular hypertrophy in patients
with severe COPD. There may be several explanations for the absence of an associati-
on between the investigated eNOS polymorphisms and electrocardiographic evidence
of right ventricular hypertrophy. The most likely explanation is that the differences in
basal NO production in patients with COPD with different eNOS genotypes, are too
small to attenuate or to prevent chronic alveolar hypoxia induced pulmonary vaso-
constriction and the development of pulmonary hypertension. This observation does
not implicate that NO does not play a role in the pathogenesis of pulmonary hyper-
tension and right ventricular hypertrophy in patients with COPD. The contribution
of the investigated eNOS polymorphism to changes in basal NO production in these
patients appears, however, to be of minor importance. Other polymorphisms of genes
responsible for vasoactive substances like polymorphisms of the angiotensin conver-
ting enzyme gene may play a more crucial role in the development of right ventricular
hypertrophy in patients with COPD. In fact we have recently shown, in the very same
population as used in the present study, that the ACE DD genotype in male patients
with COPD is negatively associated with electrocardiographic evidence of right vent-
ricular hypertrophy (24).
Moreover, it may be that not in all patients with COPD, right ventricular hyper-
trophy was identified by means of electrocardiography. It is well known that electrocar-
diography is highly specific but rather insensitive for detecting right ventricular
hypertrophy in patients with COPD (25). However, the earlier reported association
between the ACE DD genotype and right ventricular hypertrophy in the same popula-
tion makes this less likely (24).
The absence of an association between the eNOS G/T and a/b genotypes and
right ventricular hypertrophy is not a result of differences in the distribution of these
eNOS genotypes in patients with COPD compared with patients without COPD. The
distributions of the eNOS G/T and a/b genotypes found in the present study did not
significantly differ from our control group. To exclude a possible pre-COPD
confounder in the control group we have subanalyzed the data of the control group.
Analysis of the eNOS genotypes in the older people in the control group (mean age 58
years; SD, 5; n =27) did not reveal a significant change in genotype distribution
compared with the COPD group. Moreover, mean FEVj % pred in the older subgroup
of our control population was 90% (SD, 8), which is not significantly different from the
93% (SD, 8) of the total group, and far above that in the COPD group (37%). There-
fore, we think that it is very unlikely that our control group contained a COPD-prone
subpopulation.
In conclusion, in the present study we found no association between the eNOS
T or a alleles and electrocardiographic evidence of right ventricular hypertrophy in
patients with severe stable COPD.
aer
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CHAPTER 7
General discussion
7.1 INTRODUCHON ... .
In this thesis we have studied mediators that control the growth of pulmonary vascu-
lar smooth muscle cells in the development of pulmonary vascular remodeling in pul-
monary hypertension.
First, we explored the role of All in pulmonary vascular remodeling in the
animal models. We consistently found that All plays an important role in pulmonary
vascular remodeling, but not in the development of right ventricular hypertrophy
secondary to hypoxia induced pulmonary hypertension.
We extended the studies on involvement of the renin angiotensin system as well
as nitric oxide by investigating whether polymorphisms of the RAS and eNOS
contribute to the development of pulmonary hypertension and right ventricular hyper-
trophy in patients with severe COPD. We demonstrated that the ACE DD genotype is
negatively associated with electrocardiographic evidence of right ventricular hyper-
trophy in male patients with COPD.
Furthermore the data show that there is limited correlation between structural
pulmonary arterial changes and hemodynamic parameters, even if one optimizes die
measurement of pulmonary vascular remodeling.
7.2 PULMONARY ARTERY STRUCTURE AND FUNCTION
Two techniques most commonly used to determine operability in children with cong-
enital heart disease are hemodynamic evaluation by cardiac cadieterization and histo-
logical evaluation of structural pulmonary arterial changes in open lung biopsies. The-
re is, however, a great need for an optimal assessment of structural pulmonary vascular
changes and the functional consequences of this remodeling process, since important
discrepancies have been reported between structural pulmonary vascular changes and
hemodynamic parameters and clinical outcome in individual patients with congenital
heart disease (1-4). Our data, described in chapter 2, also show that in children with
congenital heart disease medial thickening of muscular pulmonary arteries and mus-
cularization of arterioles weakly correlate with pulmonary artery pressures. Moreover,
there was no correlation between preoperative hemodynamic parameters and the pre-
sence of advanced plexogenic arteriopathy.
tot
One explanation for the apparent lack of a structure-function relation could be the
fact that histological evaluation of structural pulmonary vascular changes was perfor-
med using inadequate parameters of structural pulmonary artery changes. In most
studies evaluation of structural pulmonary vascular changes in children with congeni-
tal heart disease is performed using the grading system described by Heath and
Edwards (5). The most important drawback of this grading system is that severe struc-
tural pulmonary vascular changes (grade 4 and higher) are unusual in die first two
years of life, even in the presence of severely elevated pulmonary vascular resistance
(6), which limits the value of this grading system.
Second, most studies using the morphometric approach to evaluate structural
pulmonary vascular changes express the medial wall thickness as a percentage of the
external diameter (1,2,4,7,8). This parameter does not adequately reflect changes in
medial cross-sectional area and lumen area, since the external diameter may change
during die complex process of pulmonary vascular remodeling. In Mulvany's descrip-
tion of remodeling of arteries the ratio of media area to lumen area and the lumen area
radier than medial wall thickness are essential parameters (9). A prerequisite for the
analysis of structural pulmonary vascular changes as suggested by Mulvany and
co-workers is that the analysis is performed under standard intravascular pressure and
maximal vasodilatation. At autopsy or open lung biopsies it is technically almost impos-
£ sible to process lung tissue and pulmonary arteries under these conditions. This limits
S. the value of morphometric analysis of pulmonary arteries in open lung biopsies.
£ Third, even if morphometric analysis of structural pulmonary arterial changes is
110 performed under standard intravascular pressure and maximal vasodilatation, we
found, as described in chapter 3, for the rat hypoxia- and monocrotaline models of
pulmonary hypertension, only limited correlations between changes in pulmonary
artery structure and changes in pulmonary artery pressure.
Medial thickening and muscularization of arterioles in children with congenital
heart disease, however, was associated with perioperative hypertensive crisis. Moreover,
patients with plexiform lesions showed persistent pulmonary hypertension after
surgery.
It is known that medial thickening and muscularization of arterioles is associ-
ated with increased pulmonary contractile responses (10). Constriction rather than
structural lumen narrowing of pulmonary arteries may dierefore be the major determi-
nant of an increased pulmonary artery pressure. In children with congenital heart
disease and in animal models of pulmonary hypertension, morphometric parameters
and/or grading systems of structural pulmonary vascular changes do not take into
account this functional component of the pulmonary vascular endodielium and
smooth muscle cells. The hypothesis diat may be derived from these data is that the
muscularized arterioles constitute an important determinant of pulmonary artery pres-
sure as a result of chronic hypoxia or in children widi congenital heart disease. This is
not only based on the data in children with congenital heart disease, where we found a
positive correlation between muscularization of arterioles and hypertensive crises, but
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also on the data obtained from the rat studies, where chronic hypoxia and MCT
increased both the number of muscularized arterioles and pulmonary artery pressure.
Also during ACE inhibition, which did not affect pulmonary artery pressure, a substan-
tial number of arterioles remained muscularized. Finally, in chronic hypoxic mice with
a genetic disruption of the ACE gene, the majority of arterioles remained muscularized
while the right ventricular pressure was not affected. • • • '•' •• • ' <- "•"; •'.•-=:
7.3 ROLE OF A l l IN HYPOXIA-INDUCED PULMONARY HYPERTENSION • • -
AND RIGHT VENTRICULAR HYPERTROPHY
All is produced in the lungs through the conversion of angiotensin I (AI) into All by
ACE. All induces vasoconstriction, and is known to induce structural arterial changes
like matrix protein synthesis and smooth muscle cell hypertrophy and proliferation
(11-15). In hypoxia-induced pulmonary hypertension in rats, local ACE expression is
increased in the wall of small pulmonary arteries and right ventricular ACE expression
is upregulated (16,17). ACE inhibition in rats, in part reverses established hypoxi-
a-induced pulmonary hypertension probably via inhibition of pulmonary vascular
smooth muscle cell proliferation and/or growth (18).
From the data described in chapters 3 and 4, where we lowered the activity of
ACE by a pharmacologic (ACE inhibitor) or genetic intervention (tissue ACE-
deficient mice) (19) we conclude that ACE, and therefore also All, plays a role in
hypoxia-induced pulmonary vascular remodeling, but not in the development of
pulmonary hypertension and right ventricular hypertrophy. In theory, alternative All
generating pathways, like All formation by chymase, could play a role in constriction of
partially muscularized arterioles and/or in the development of right ventricular hyper-
trophy (20).
Our first conclusion from these data is that the effect of a lowered ACE activity
on the pulmonary vascular structure is a direct one, and not due to an effect on pulmo-
nary artery pressure. All is known to stimulate proliferation of human pulmonary
artery smooth muscle cells via the angiotensin type 1 receptor (21). Recent data suggest
that All also induces muscularization of arterioles in the chick embryo chorio-allantoic
membrane (thesis le Noble 1997). The reduction of the percentage of completely
muscularized arterioles in our animal models is most likely a result of inhibition of
pulmonary vascular smooth muscle cell proliferation and/or growth, as suggested by
Nong and co-workers (18). Recent data show that hypoxia-inducible factor 1 (HIF-1)
is an important mediator of transcriptional responses to decreased oxygen availability.
Several hypoxia-inducible genes like those encoding erythropoietin, vascular endothe-
lial growth factor, inducible nitric oxide synthase, and endothelin-1 contain function-
ally important HIF-1 binding sites (22). Whether the ACE gene contains a HIF-1
binding site or affects the expression of HIF-1 in any other way is at this moment
unknown and warrants further investigation.
Second, these data show that despite a reduction of the percentage of completely mus-
cularized arterioles there was no effect on pulmonary artery pressure/mean right vent-
ricular pressure or right ventricular hypertrophy. As suggested above, constriction of
partially muscularized arterioles may obscure effects of a reduced percentage of com-
pletely muscularized arterioles on the pulmonary artery and/or right ventricular pres-
sure and right ventricular hypertrophy.
Also in patients with COPD and secondary pulmonary hypertension most
studies report that treatment with ACE inhibitors does not improve survival and has no
clinically significant effect on pulmonary hemodynamics (23-26). A possible explana-
tion for the lack of effect of ACE inhibitors alone could be that, as we have shown in
chronic hypoxic rats and mice, attenuation of this pulmonary vascular remodeling
process alone is not enough to attenuate pulmonary artery pressure and right
ventricular hypertrophy probably because of a persistent vasoconstrictive component.
In theory, optimal treatment of pulmonary hypertension in patients with COPD
should include a selective pulmonary vasodilator to attenuate the pulmonary vasocon-
strictive component in combination with an ACE inhibitor to attenuate the develop-
ment of structural pulmonary vascular changes. Indeed, oxygen, a potent pulmonary
vasodilator, in combination with the ACE inhibitor captopril has been shown to reduce
the pulmonary artery pressure and improved tissue oxygenation, although this study
^ was based on 5 patients only (27).
i ^ ~ ~ 7 .4 POTENTIAL ROLE OF GENE POLYMORPHISMS I N HYPOXIA- INDUCED
PULMONARY HYPERTENSION • '. .. .., . ^  ;-,;, -• .
COPD is a complex disease and likely results from a complex interplay between gene-
tic and environmental factors. Polymorphisms of genes, like the polymorphisms of
the apantitrypsin gene may be associated with altered susceptibility to disease, to dis-
ease severity, and to the response to treatment (28,29). Also a genetic predisposition
in some instances of primary pulmonary hypertension (PPH) has been described, sin-
ce a familial form of PPH is characterized by linkage to chromosome 2q31-q32 (30).
In the systemic circulation polymorphisms of genes of the RAS and eNOS are
associated widi an increased risk to cardiovascular diseases (31 -38). With respect to the
pulmonary circulation, very few data exist on a potential association between polymor-
phisms of genes of the RAS and eNOS and pulmonary hypertension, right ventricular
hypertrophy and right ventricular function (39).
In chapters 5 and 6, we therefore investigated potential associations between
polymorphisms of the angiotensinogen gene, the ACE gene, die angiotensin type I
receptor gene (chapter 5) and the eNOS gene (chapter 6) and electrocardiographic
evidence of right ventricular hypertrophy. We have shown that the ACE DD polymor-
phism, but not die AGT i R, AGT and eNOS polymorphisms, are negatively associated
with electrocardiographic evidence of right ventricular hypertrophy in male patients
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with COPD. Right ventricular hypertrophy in our studies was determined by electro-
cardiographic criteria which is a specific but rather insensitive method. We were there-
fore unable to discriminate whether male patients with COPD and the ACE DD
genotype had lower pulmonary arterial pressures or showed less adaptive right
ventricular hypertrophy than did male patients with the non-DD genotype. Data of a
recent study by Morrell and coworkers (40) show that people witli hypoxia-induced
pulmonary hypertension who were living at high altitude had a 6-fold higher frequency
of the ACE II genotype compared with those without. Based on these findings we
believe that it is more likely that in our study patients with COPD and the ACE DD
genotype have lower pulmonary arterial pressures and as a consequence show less right
ventricular hypertrophy than do patients with COPD with the non-DD genotype. Our
data in the rat (chapter 3) and the mouse (chapter 4), however, suggest that pulmonary
artery pressure will not be affected. The pulmonary artery pressures in the study of
Morrell were measured during right heart catheterization. Future studies using the
non-invasive and sensitive echo-doppler technique (41) to determine pulmonary artery
pressure may provide a definitive answer to the question whether pulmonary artery
pressures are changed in male COPD patients with the DD genotype.
Gender and susceptibility to develop pulmonary hypertension in patients
with COPD : -••••••
The negative association between the ACE DD genotype and electrocardiographic
evidence of right ventricular hypertrophy was only present in male but not in female
patients with COPD. It is known that the female sex is a cardioprotective factor and
that estrogens modulate the development of cardiac hypertrophy (42). As most female
patients with COPD in our study were postmenopausal, estrogens may mask or delay
a potential association between the ACE genotype and right ventricular hypertrophy
in female patients with COPD. Indeed several papers show that female sex hormones
protect against pulmonary vascular remodeling and right ventricular hypertrophy in
both hypoxia and MCT induced pulmonary hypertension (43,44). In the study of
Morrell (40), who showed that hypoxia-induced pulmonary hypertension had a
6-fold higher frequency of the ACE II genotype compared with those without, only
males were included and it therefore provides no further evidence for a gender diffe-
rence with respect to the ACE genotypes and development of pulmonary hypertensi-
on and/or right ventricular hypertrophy as we have shown in our study in patients
with COPD.
7 . 5 C O N C L U S I O N S A N D F U T U R E P E R S P E C T I V E S * . « . ~ : , -.. . - . v ' v .:••••
In conclusion, we found limited correlations between structural pulmonary vascular
changes and pulmonary artery pressure. The best candidate that may improve the
structure-function correlation in the lungs is the muscularized arteriole.
Second, angiotensin II plays a crucial role in the development of hypoxia-
induced pulmonary vascular remodeling, but not in the development of pulmonary
hypertension and right ventricular hypertrophy. The exact padiway how angiotensin II
induces changes in pulmonary artery structure is not known. HIF-1 could be an impor-
tant mediator in these hypoxia-induced structural pulmonary vascular changes.
Third, the ACE DD genotype was negatively associated with electrocardio-
graphic evidence of right ventricular hypertrophy, but only in male patients with
COPD. Analysis of polymorphisms of genes of vasoactive mediators may play an
important role in the risk stratification and medical management of pulmonary hyper-
tension in patients with congenital heart disease and COPD. The finding of gender
differences in the susceptibility of patients with COPD for the development of right
ventricular hypertrophy may also open up new strategies for therapy.
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Pulmonary hypertension is a common complication of cardiopulmonary diseases. All
patients with chronic pulmonary hypertension, irrespective of the etiology, have
structural pulmonary vascular changes, commonly called pulmonary vascular remo-
deling. The pathogenesis of pulmonary vascular remodeling in patients with chronic
obstructive pulmonary disease (COPD) and in children with congenital heart disease
is poorly understood. Moreover, discrepancies between pulmonary hemodynamics
and pulmonary artery structure have been described in children with congenital heart
disease and animal models of pulmonary hypertension. In this thesis, experiments
were performed to study the role of angiotensin II (All) in hypoxia-induced pulmona-
ry vascular remodeling as occurs in patients with COPD. Furthermore, we studied the
correlation between pulmonary vascular remodeling and pulmonary artery pressure.
Finally, we studied the role of polymorphisms of genes of the renin angiotensin sy-
stem (RAS) and endothelial nitric oxide synthase (eNOS) in the development of pul-
monary hypertension in patients with severe COPD.
In chapter 2 we determined the correlation between pulmonary hemo-
dynamics, structural pulmonary arterial changes and outcome in 47 children with
congenital heart disease. Structural pulmonary arterial changes were evaluated in open
lung biopsies or in lung tissue obtained at autopsy. We found only limited correlations
between hemodynamic data and structural pulmonary vascular changes. Perioperative
mortality, associated with acute pulmonary hypertensive crises, positively correlated
with increased arterial muscularity, but could not be predicted from preoperative
hemodynamics or the presence of advanced plexogenic arteriopathy. Only plexiform
lesions were predictive for persistent pulmonary hypertension.
In chapter 3 we correlated structural pulmonary vascular changes of muscular
pulmonary arteries and arterioles in chronic hypoxic and monocrotaline (MCT)
treated rats with pulmonary artery pressure and right ventricular hypertrophy. Discrep-
ancies between pulmonary artery pressure and pulmonary artery structure may be
explained by the fact that constriction, rather than structural narrowing of pulmonary
arteries, plays a role in the rise of the pulmonary artery pressure. We therefore
performed morphometrical analysis on pulmonary arteries fixed under standard
intravascular pressure and maximal vasodilatation. An alternative explanation for
discrepancies between pulmonary artery pressure and pulmonary anery structure is
that previous studies have focussed on the wrong parameters of structural pulmonary
vascular changes. The medial wall thickness expressed as a percentage of the arterial
external diameter does not adequately reflect changes in medial cross-sectional area and
lumen area since the external diameter of arteries may also changes during the process of
vascular remodeling. Therefore, morphometrical analysis of structural pulmonary
vascular changes was performed according to the concept of Mulvany in which the
media area to lumen area ratio and lumen area are essential parameters, rather than
medial wall thickness. We observed that MCT, in contrast to chronic hypoxia, induces
structural changes of muscular pulmonary arteries which may contribute to an increase
in pulmonary artery pressure and right ventricular hypertrophy. The ACE inhibitor
captopril had no effect on MCT-induced pulmonary hypertension, right ventricular
hypertrophy and pulmonary artery remodeling. In chronic hypoxic rats, however,
captopril prevented an increase in medial cross-sectional area of muscular pulmonary
arteries and attenuated the increase in the percentage of muscularized arterioles,
without any effect on pulmonary artery pressure and right ventricular hypertrophy.
In chapter 4 we investigated the effects of chronic hypoxia on pulmonary
vascular remodeling and its functional consequences in tissue ACE-deficient mice.
Under chronic hypoxic conditions the percentage of completely muscularized arteri-
oles was lower in tissue ACE-deficient mice compared to wild-type animals whereas the
mean right ventricular pressure and the extent of right ventricular hypertrophy was not
different. We concluded that pulmonary vascular remodeling is attenuated in tissue
ACE-deficient mice compared to wild-type animals. Local production of angiotensin
II by ACE in pulmonary arterioles plays an important role in the pathogenesis of
hypoxia-induced pulmonary vascular remodeling.
In chapters 5 and 6 we studied the potential role of polymorphisms of genes of
2> the renin angiotensin system (RAS) and endothelial nitric oxide synthase (eNOS) in the
development of pulmonary hypertension induced right ventricular hypertrophy in
patients with severe COPD. Polymorphisms of the RAS included the M^5 T polymor-
120 phism of the angiotensinogen gene, the 287 base-pair insertion (I)/ deletion (D) poly-
morphism at intron 16 of the ACE gene and the A " ^ C polymorphism in the
angiotensin II type 1 receptor gene. The eNOS gene polymorphisms included a
guanine to thymine substitution within exon 7 and a 27 base-pair repeat polymorphism
in the fourth intron of the eNOS gene. We observed that only the ACE DD genotype
was negatively associated with electrocardiographic evidence of right ventricular hyper-
trophy but only in male patients with COPD. The other polymorphisms investigated
did not show an association with electrocardiographic evidence of right ventricular
hypertrophy.
Finally, in chapter 7 the results are discussed and the main conclusions of this
thesis are summarized.
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Samenvatting ' vy
Pulmonale hypertensie is een veel voorkomende en soms levensbedreigende compli-
catie die kan optreden bij kinderen met een aangeboren hartafwijking waarbij er sprake
is van een toegenomen bloeddoorstroming door de longarterien en patienten met chro-
nisch obstructief longlijden (COPD). Patienten met chronische pulmonale hyper-
tensie hebben, onafhankelijk van de oorzaak, structurele longvaatveranderingen;
afwijkingen die ook wel omschreven worden als remodellering van de longvaatwand.
De pathogenese van dit remodelleringsproces is niet bekend. Bovendien zijn er discre-
panties beschreven tussen structurele longvaatveranderingen bij kinderen met een
aangeboren hartafwijking en drukken gemeten in deze longarterien. In dit proefschrift
worden experimenten beschreven met als doel om meer inzicht te krijgen in de regulatie
van dit remodellerings proces van longarterien. Allereerst hebben we de resultaten van
hemodynamische evaluatie en structurele longvaarveranderingen met elkaar verge-
leken in zowel diermodellen voor pulmonale hypertensie alsmede in kinderen met een
aangeboren hartafwijking. Vervolgens wordt de rol van angiotensine II (All) bestu-
deerd in dit remodellerings proces.Tenslotte, wordt de rol van varianten (polymor-
fismen) van genen van het renine angiotensine systeem en endotheliaal stikstofoxide
synthase (eNOS) bestudeerd in relatie tot de ontwikkeling van pulmonale hypertensie
bij patienten met COPD.
Inhoofdstuk2 werden hemodynamische gegevens gecorreleerd met structurele
longvaatveranderingen en het klinisch beloop van 47 kinderen met een aangeboren
hartafwijking.
Longvaatveranderingen werden bestudeerd in open longbiopten of longweefsel
verkregen bij obductie. Er bleek sprake te zijn van een slechte correlatie tussen hemody-
namische parameters en structurele longvaatveranderingen. Perioperatieve mortaliteit,
geassocieerd met zogenaamde pulmonale hypertensieve crisen, bleek positief te corre-
leren met een toegenomen verdikking van de wand van longarterien en arteriolen. Peri-
operatieve mortaliteit kon echter niet worden voorspeld op grond van preoperatieve
hemodynamische gegevens en/of structurele longvaarveranderingen in een vergevor-
derd stadium.
Alleen de aanwezigheid van zogenaamde plexiforme afwijkingen van longarte-
rien was in alle gevallen geassocieerd met het persisteren van pulmonale hypertensie.
De correlatie tussen structurele longvaatveranderingen en de druk in de longar-
terien en rechter ventrikelwand hypertrofie werd beschreven in hoofdstuk 3. De experi-
menten werden uitgevoerd in een tweetal veelvuldig gebruikte ratten modellen, te
weten het chronische alveolaire hypoxie model en het door monocrotaline (MCT)
geinduceerde pulmonale hypertensie model. Een mogelijke oorzaak van discrepanties
tussen structurele longvaatveranderingen en hemodynamische gegevens zou gelegen
kunnen zijn in het feit dat morfometrische analyse van longvaatveranderingen niet
onder optimale perfusie condities werd uitgevoerd. Doel van dit onderzoek was het om
strucrurele longvaarveranderingen te bestuderen onder gestandaardiseerde omstandig-
heden. Morfometrie werd verricht nadat de longvaten waren gefixeerd onder maximale
vaarverwijding en standaard druk. Bovendien werden parameters als de ratio media
oppervlakte/lumen oppervlakte en lumen oppervlakte gebruikt, daar deze parameters
de gevolgen van het remodellerings proces voor de vaatwand nauwkeuriger weergeven.
De in de literatuur veel gebruikte ratio media dikte/vaatwand diameter is een minder
nauwkeurige parameter, omdat tijdens het remodellerings proces van de vaatwand de
diameter van het vat ook kan veranderen. Morfometrische analyse uitgevoerd onder
deze omstandigheden toonde aan dat alleen MCT geinduceerde media verdikking van
longarterien resulteerde in een reductie van het lumen oppervlak. Een tweede doel van
het in hoofdstuk 3 beschreven onderzoek was het bestuderen van de rol van All in het
remodellerings proces. De angiotensine I converting enzyme remmer captopril had
geen invloed op MCT geinduceerde structured longvaarveranderingen, de mate van
pulmonale hypertensie en de mate van rechter ventrikelwand hypertrofie. Onder chro-
nische hypoxische omstandigheden voorkwam captopril vaatwandverdikking van
musculaire longarterien en verminderde het aantal gemusculariseerde arteriolen, echter
zonder effect op de druk in de longarterien en zonder effect op de mate van rechter vent-
B rikelwand hypertrofie. '•"
• In hoofdstuk 4 werden de effecten van chronische hypoxie beschreven op het
• remodellerings proces van arteriolen in genetisch gemanipuleerde (weefsel
5 ACE-deficiente) muizen. Onder chronische hypoxische omstandigheden was het
122 percentage arteriolen dat volledig omgeven was door een laag gladdespiercellen
(gemuscularizeerde arteriolen) lager in weefsel ACE-deficiente muizen vergeleken met
de controle groep. De minder uitgesproken remodellering van arteriolen in weefsel
ACE deficiente muizen had echter geen invloed op drukken in longarterien en op de
mate van rechter ventrikelwand hypertrofie. Uit deze studie kan worden geconcludeerd
dat locale productie van All door ACE in longarteriolen een belangrijke rol speelt bij de
pathogenese van chronische hypoxie-gei'nduceerde remodellering van deze arteriolen.
In de hoofdstukken 5 en 6 werd de rol van varianten (polymorfismen) van
genen van het renine angiotensine systeem (RAS) en endotheliaal stikstofoxide
synthase (eNOS) bestudeerd bij het ontstaan van, door pulmonale hypertensie geindu-
ceerde, rechter ventrikelwand hypertrofie bij patienten met COPD. Verschillende vari-
anten van genen het het RAS werden geanalyseerd. Het betrof een
thymine/cytosine-puntmutatie op positie 704 van exon 2 van het angiotensinogeen
gen leidende tot een aminozuur substitutie waarbij methionine op positie 235
vervangen wordt door threonine (M^T-variant), een 287 baseparen insertie
(I)/deletie (D) variant in intron 16 van het ACE gen en een A " ^ C variant in het gen
coderend voor de angiotensine II type 1 receptor waarbij op positie 1166 de base
adenine vervangen is door cytosine. Varianten van het eNOS gen waren een
guanine/thymine substitutie in exon 7 (eNOS G/T) en een 27 baseparen verschillende
variant in intron 4 (eNOS a/b). Electrocardiografische criteria werden gebruikt om
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eventuele rechterventrikelwand hypertrofie aan te tonen. Bij 36% van de patienten met
COPD bleek er sprake te zijn van rechterventrikelwand hypertrofie. Van alle onder-
zochte varianten van genen van het RAS en eNOS kon alleen een negatieve associatie
worden aangetoond tussen mannelijke patienten met COPD met het ACE DD geno-
type en rechterventrikelwand hypertrofie.
Tenslotte worden in hoofdstuk 7 de resultaten van de hierboven beschreven
hoofdstukken met elkaar in verband gebracht en worden er enkele suggesties gedaan
om te komen tot een betere inventarisatie van structurele longvaatverandering en
behandelingsmogelijkheden om deze structurele longvaatveranderingen te voorkomen
of te verminderen.
k - ' f
if
1*1 ll"i
- !
r .
125
Dankwoord
Dit proefschrift is tot stand gekomen dankzij de unieke samenwerking tussen mede-
werkers van de vakgroepen pathologie en farmacologie. Enkele mensen echter wil ik in
het bijzonder bedanken:
Allereerst mijn promotor Mat Daemen. Beste Mat, snel, helder en vaak geniaal. Veel
ideeen ontstonden tijdens een rondje Observant of Savelsbos. Dit is zowel het proef-
schrift als ook het lichaam ten goede gekomen.
Vervolgens mijn promotor Jos Smits. Beste Jos, kritisch, meedenkend en in combinatie
met Mat uniek maar vaak wat lastig voor de kandidaat.
Prof. dr. C.A. Wagenvoort, die helaas kort na het tot stand komen van het eerst manu-
script overleed. Een beter leermeester voor het leren beoordelen van longvaatverande-
ringen was er niet.
De leden van de beoordelingscommissie Prof. dr. J.G.R. De Mey, Prof. dr. C.E.
Blanco, Prof. dr. P.W. de Leeuw. Prof. dr. W.J. Mooi en Dr. G.J. Wesseling wil ik
bedanken voor het kritisch doorlezen van het manuscript.
Peet, Mo, An en Loes. DNA isoleren en PCR technieken leerden jullie me snel, echter
het leren bereken van verdunningen duurde langer.
Jacques en Peter, in combinatie op het lab bijna net zo dodelijk als de combinatie
Smits-Daemen. Nicole dank voor de hulp bij alle drukmetingen.
Emiel Wouters ben ik dank verschuldigd voor het tot stand komen van contacten met
het Astma Centrum Hornerheide. Herman-Jan Pennings bedankt voor de hulp bij het
invoeren van patientengegevens en beiden bedankt voor het kritisch doorlezen van de
manuscripten die hieruit voortkwamen.
Emile Cheriex en Petra van Pol voor het beoordelen van de ECG's. Het zal wel altijd
"Petra van de P-toppen" blijven.
John Hess en Rolf Berger stonden misschien wel aan de basis van dit proefschrift. Zij
hadden vanaf het begin een kritische houding ten aanzien van een relatie tussen long-
vaatstructuur en hemodynamische consequenties en naar later bleek deels terecht.
Cor Beek, Jack Cleutjens, Wendy Aartsen, Wilko Spiering, Jacques Baltis en mensen
die ik vergeten ben dank voor de hulp met computers, morfometrie, polymorfismen,
TWACE muizen, afbranden, etc.
De paranimfen en maten Rob Homburg en Joep Gerards.
Mijn schoonouders die me er van konden overtuigen om geneeskunde te gaan
studeren.
Mijn vader voor alle "zetjes" in de rug vooral tijdens mijn middelbare schooltijd. Mijn
moeder die als enige begreep dat de studie geneeskunde meer inhield dan de bloedsom-
loop van de kikker.
Tenslotte de ouwe Dibbes en de oelewappers: het viel eigenlijk aJlemaaJ wel mee!
bioov-'
-"• f i , -* i: . ,cn ••-'-;>!?
' { : . ; • . ' ; ., ( . • •
' • " • • ' - • " i ' • • • • - > • ' > • " : . • ' .
. I . ' ' . - ! . . . ' • • '
• < - • » : • • , / ! . . •
.';••) ,- ':ji;-. ' . iVt'. '- i;'.-.»:.i.>
127
Publications
This thesis is based on the following papers '••'• '"•*'•'-'••*
1. Berger RMF, van-Suylen RJ, van-Zuuren DAK, Wagenvoort CA, Mooi WJ,
Bogers AJJC, Hess J. Evaluation of pulmonary hemodynamics and structure
and their relation with clinical outcome in children with congenital heart dis-
ease. Submitted.
2. van-Suylen RJ, Smits JFM, Daemen MJAP. Pulmonary artery remodeling dif-
fers in hypoxia- and monocrotaline induced pulmonary hypertension. /4ra. /
/?«/>«>. Cm. Gw* Af«* 1998:157:1423-1428.
3. van-Suylen RJ, Aartsen W, Smits JFM, Daemen MJAP. Dissociation of pul-
monary vascular remodeling and right ventricular pressure in tissue
ACE-deficient mice in conditions of chronic alveolar hypoxia. Submitted.
4. van-Suylen RJ, Wouters EF, Pennings HJ, Cheriex EC, van-Pol PE,
Ambergen AW, Vermelis A, Daemen MJ. The DD genotype of the angioten-
sin converting enzyme gene is negatively associated with right ventricular hy-
pertrophy in male patients with chronic obstructive pulmonary disease.j4w;. / .
/?«/>*>. Crz>. GwAfa/. 1999:159:1791-1795.
5. van-Suylen RJ, Pennings HJ, Wouters EF, Cheriex EC, van-Pol PE,
Ambergen AW, Spiering W, Aarts PL, Daemen MJAP. Endothelial nitric ox-
ide synthase gene polymorphisms and right ventricular hypertrophy in pa-
tients with chronic obstructive pulmonary disease. Submitted.
Moreover, the author of this thesis is first author on 3 papers and co-author on
28 papers.
Curriculum Vitae
Robert Jan van Suylen j ^ * ^ j no
1957 -••»•-•* * Geboren the Prabumulih (Indonesia) > u . - . / o . . , . • t
1976 Eindexamen HAVO Hertog Jan College Valkenswaard
1976 - 1980 Academie voor Lichamelijke Opvoeding KALO te Tilburg
1980 - 1982 Militaire Dienst
1982 Staatsexamen Natuurkunde en Scheikunde i>j iiv-rtf-
1982 - 1988 Studie Geneeskunde Erasmus Universiteit Rotterdam ; ,
1986 Doctoraal examen Geneeskunde
1988 - .-_ Artsexamen
1988 - 1989 A G N I O Heelkunde Ac. Ziekenhuis Dijkzigt Rotterdam
1989 - 1994 Opleiding Pathologie Ac. Ziekenhuis Dijkzigt Rotterdam
(Opleiders Prof. dr. R.O. van der Heul, Prof. dr. F.T. Bosman)
1994 - 1995 Staflid afdeling pathologie Ac. Ziekenhuis Dijkzigt Rotterdam
1995 - heden Staflid afdeling pathologie Ac. Ziekenhuis Maastricht ,., ,.
. • • • ! ; • - "
- t - - ; ; • , . ,


